US20130090472A1 - Gold complexes for use in the treatment of cancer - Google Patents
Gold complexes for use in the treatment of cancer Download PDFInfo
- Publication number
- US20130090472A1 US20130090472A1 US13/704,894 US201113704894A US2013090472A1 US 20130090472 A1 US20130090472 A1 US 20130090472A1 US 201113704894 A US201113704894 A US 201113704894A US 2013090472 A1 US2013090472 A1 US 2013090472A1
- Authority
- US
- United States
- Prior art keywords
- iii
- gold
- compound
- bis
- hexafluorophosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 64
- 201000011510 cancer Diseases 0.000 title claims abstract description 54
- 150000001875 compounds Chemical class 0.000 claims abstract description 143
- -1 cyano, carboxyl Chemical group 0.000 claims abstract description 66
- 125000003118 aryl group Chemical group 0.000 claims abstract description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 33
- 150000001408 amides Chemical class 0.000 claims abstract description 28
- 150000001450 anions Chemical class 0.000 claims abstract description 27
- 125000001424 substituent group Chemical group 0.000 claims abstract description 26
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 18
- 150000002367 halogens Chemical class 0.000 claims abstract description 18
- 150000003973 alkyl amines Chemical class 0.000 claims abstract description 16
- 150000002148 esters Chemical class 0.000 claims abstract description 16
- 150000001412 amines Chemical class 0.000 claims abstract description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 12
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 8
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 7
- 150000003573 thiols Chemical class 0.000 claims abstract description 7
- 239000005922 Phosphane Substances 0.000 claims abstract description 6
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000004185 ester group Chemical group 0.000 claims abstract description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
- 230000036961 partial effect Effects 0.000 claims abstract description 6
- 229910000064 phosphane Inorganic materials 0.000 claims abstract description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 6
- 150000003568 thioethers Chemical class 0.000 claims abstract description 6
- CBMIPXHVOVTTTL-UHFFFAOYSA-N gold(3+) Chemical compound [Au+3] CBMIPXHVOVTTTL-UHFFFAOYSA-N 0.000 claims description 98
- 239000003446 ligand Substances 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 51
- 125000002648 azanetriyl group Chemical group *N(*)* 0.000 claims description 37
- 239000000460 chlorine Substances 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 239000002262 Schiff base Substances 0.000 claims description 11
- 125000005207 tetraalkylammonium group Chemical group 0.000 claims description 11
- 150000004985 diamines Chemical class 0.000 claims description 9
- 150000004820 halides Chemical class 0.000 claims description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
- 229910002651 NO3 Inorganic materials 0.000 claims description 8
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 7
- 229910003803 Gold(III) chloride Inorganic materials 0.000 claims description 7
- RJHLTVSLYWWTEF-UHFFFAOYSA-K gold trichloride Chemical compound Cl[Au](Cl)Cl RJHLTVSLYWWTEF-UHFFFAOYSA-K 0.000 claims description 7
- 229940071240 tetrachloroaurate Drugs 0.000 claims description 7
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- IJUJQZNGLZFJGP-UHFFFAOYSA-N pyrrol-2-imine Chemical compound N=C1C=CC=N1 IJUJQZNGLZFJGP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 5
- 150000008648 triflates Chemical class 0.000 claims description 5
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 5
- 229910052727 yttrium Inorganic materials 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 150000001728 carbonyl compounds Chemical class 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910000071 diazene Inorganic materials 0.000 claims description 4
- YAOXYADITCJWPJ-UHFFFAOYSA-J gold(3+);tetrabutylazanium;tetrachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Au+3].CCCC[N+](CCCC)(CCCC)CCCC YAOXYADITCJWPJ-UHFFFAOYSA-J 0.000 claims description 4
- 150000002823 nitrates Chemical class 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229910052721 tungsten Inorganic materials 0.000 claims description 4
- JPHIRTNZTXYJEI-CZCYGEDCSA-N C=1C=CNC=1/C=N/CC(OCC)C\N=C\C1=CC=CN1 Chemical compound C=1C=CNC=1/C=N/CC(OCC)C\N=C\C1=CC=CN1 JPHIRTNZTXYJEI-CZCYGEDCSA-N 0.000 claims description 3
- 238000000638 solvent extraction Methods 0.000 claims description 3
- JKEWKJLOBAOJJX-KAVGSWPWSA-N C=1C=CNC=1/C=N/CC(Cl)C\N=C\C1=CC=CN1 Chemical compound C=1C=CNC=1/C=N/CC(Cl)C\N=C\C1=CC=CN1 JKEWKJLOBAOJJX-KAVGSWPWSA-N 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 131
- 210000004027 cell Anatomy 0.000 description 93
- 239000010931 gold Substances 0.000 description 67
- 108020004414 DNA Proteins 0.000 description 59
- 239000003814 drug Substances 0.000 description 47
- 229940079593 drug Drugs 0.000 description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 41
- 239000000243 solution Substances 0.000 description 41
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 40
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 40
- 229960004316 cisplatin Drugs 0.000 description 38
- 230000003013 cytotoxicity Effects 0.000 description 37
- 231100000135 cytotoxicity Toxicity 0.000 description 37
- 239000002574 poison Substances 0.000 description 37
- 150000002466 imines Chemical class 0.000 description 36
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 36
- 231100000614 poison Toxicity 0.000 description 36
- 239000013522 chelant Substances 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000002246 antineoplastic agent Substances 0.000 description 29
- 0 CN(C)C(S1)S*1Cl Chemical compound CN(C)C(S1)S*1Cl 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 230000001472 cytotoxic effect Effects 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 21
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 20
- 229940127089 cytotoxic agent Drugs 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 230000006907 apoptotic process Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 102000003915 DNA Topoisomerases Human genes 0.000 description 16
- 108090000323 DNA Topoisomerases Proteins 0.000 description 16
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 16
- 230000003197 catalytic effect Effects 0.000 description 16
- 231100000433 cytotoxic Toxicity 0.000 description 16
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 15
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 15
- 229940127093 camptothecin Drugs 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000013078 crystal Substances 0.000 description 15
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 231100000673 dose–response relationship Toxicity 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 12
- ZSKGQVFRTSEPJT-UHFFFAOYSA-N pyrrole-2-carboxaldehyde Chemical compound O=CC1=CC=CN1 ZSKGQVFRTSEPJT-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- 101710183280 Topoisomerase Proteins 0.000 description 11
- 238000012512 characterization method Methods 0.000 description 11
- 239000002184 metal Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 231100000111 LD50 Toxicity 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 10
- 229940041181 antineoplastic drug Drugs 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000017074 necrotic cell death Effects 0.000 description 10
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 9
- 230000010534 mechanism of action Effects 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 description 8
- 150000002678 macrocyclic compounds Chemical class 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 8
- 238000002390 rotary evaporation Methods 0.000 description 8
- BYGGNODLDKCAPB-UHFFFAOYSA-N 3h-pyrrol-2-amine Chemical compound NC1=NC=CC1 BYGGNODLDKCAPB-UHFFFAOYSA-N 0.000 description 7
- 229930192392 Mitomycin Natural products 0.000 description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- 229960004132 diethyl ether Drugs 0.000 description 7
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 7
- 229960005542 ethidium bromide Drugs 0.000 description 7
- 230000009036 growth inhibition Effects 0.000 description 7
- 229960004857 mitomycin Drugs 0.000 description 7
- 230000004962 physiological condition Effects 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 230000007018 DNA scission Effects 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 6
- 229960000975 daunorubicin Drugs 0.000 description 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 6
- 230000002349 favourable effect Effects 0.000 description 6
- 230000001738 genotoxic effect Effects 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229910021645 metal ion Inorganic materials 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000005316 response function Methods 0.000 description 6
- YBRBMKDOPFTVDT-UHFFFAOYSA-O tert-butylammonium Chemical compound CC(C)(C)[NH3+] YBRBMKDOPFTVDT-UHFFFAOYSA-O 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 5
- 150000004753 Schiff bases Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 229960005420 etoposide Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical compound [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 239000012625 DNA intercalator Substances 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009920 chelation Effects 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 231100000024 genotoxic Toxicity 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 231100000027 toxicology Toxicity 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000002424 x-ray crystallography Methods 0.000 description 4
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 3
- IHBRVCYAXKKVNJ-UHFFFAOYSA-N 2-chloropropane-1,3-diamine;dihydrochloride Chemical compound Cl.Cl.NCC(Cl)CN IHBRVCYAXKKVNJ-UHFFFAOYSA-N 0.000 description 3
- LHYPCRYZSCFULV-UHFFFAOYSA-N 2-ethoxypropane-1,3-diamine Chemical compound CCOC(CN)CN LHYPCRYZSCFULV-UHFFFAOYSA-N 0.000 description 3
- FEGNWYCKJMXSLY-UHFFFAOYSA-N 2-ethoxypropane-1,3-diamine;dihydrochloride Chemical compound Cl.Cl.CCOC(CN)CN FEGNWYCKJMXSLY-UHFFFAOYSA-N 0.000 description 3
- 206010048610 Cardiotoxicity Diseases 0.000 description 3
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 229910003771 Gold(I) chloride Inorganic materials 0.000 description 3
- 101000830681 Homo sapiens DNA topoisomerase 1 Proteins 0.000 description 3
- 238000004566 IR spectroscopy Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 3
- 229960005207 auranofin Drugs 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 3
- 231100000259 cardiotoxicity Toxicity 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 3
- YVDHZBIHOIHMHD-UHFFFAOYSA-K gold(3+) tricarbamodithioate Chemical class [Au+3].NC([S-])=S.NC([S-])=S.NC([S-])=S YVDHZBIHOIHMHD-UHFFFAOYSA-K 0.000 description 3
- 238000007417 hierarchical cluster analysis Methods 0.000 description 3
- 102000056859 human TOP1 Human genes 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000009830 intercalation Methods 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 239000012454 non-polar solvent Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 201000010174 renal carcinoma Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 2
- 238000004293 19F NMR spectroscopy Methods 0.000 description 2
- DRGAZIDRYFYHIJ-UHFFFAOYSA-N 2,2':6',2''-terpyridine Chemical compound N1=CC=CC=C1C1=CC=CC(C=2N=CC=CC=2)=N1 DRGAZIDRYFYHIJ-UHFFFAOYSA-N 0.000 description 2
- JFJNVIPVOCESGZ-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=N1 JFJNVIPVOCESGZ-UHFFFAOYSA-N 0.000 description 2
- NOLCMKMKOIHBAA-UHFFFAOYSA-N 2-chloropropane-1,3-diamine Chemical compound NCC(Cl)CN NOLCMKMKOIHBAA-UHFFFAOYSA-N 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 2
- 238000004679 31P NMR spectroscopy Methods 0.000 description 2
- KMWCSNCNHSEXIF-UHFFFAOYSA-N 5-methyl-1h-imidazole-4-carbaldehyde Chemical compound CC=1N=CNC=1C=O KMWCSNCNHSEXIF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- NGEHEGWOPCIIQY-UHFFFAOYSA-N CC(CN)CN.F Chemical compound CC(CN)CN.F NGEHEGWOPCIIQY-UHFFFAOYSA-N 0.000 description 2
- 125000006414 CCl Chemical group ClC* 0.000 description 2
- 108020005197 Catenated DNA Proteins 0.000 description 2
- 108091060290 Chromatid Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N N.N.[W] Chemical compound N.N.[W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229910001914 chlorine tetroxide Inorganic materials 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 210000004756 chromatid Anatomy 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- ZTVGSRJAMNTBPU-UHFFFAOYSA-N gold(3+) 3H-pyrrol-2-ylazanide Chemical class [Au+3].N=C1CC=C[N-]1.N=C1CC=C[N-]1 ZTVGSRJAMNTBPU-UHFFFAOYSA-N 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- PFRDRCIPKPEULG-UHFFFAOYSA-N imidazol-2-imine Chemical compound N=C1N=CC=N1 PFRDRCIPKPEULG-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002687 intercalation Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000006263 metalation reaction Methods 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Natural products NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-P trimethylenediaminium Chemical compound [NH3+]CCC[NH3+] XFNJVJPLKCPIBV-UHFFFAOYSA-P 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JRCLCXAVSVCEQC-UHFFFAOYSA-N $l^{1}-oxidanylformaldehyde Chemical group [O]C=O JRCLCXAVSVCEQC-UHFFFAOYSA-N 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- DDHUNHGZUHZNKB-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diamine Chemical compound NCC(C)(C)CN DDHUNHGZUHZNKB-UHFFFAOYSA-N 0.000 description 1
- VEUMANXWQDHAJV-UHFFFAOYSA-N 2-[2-[(2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol Chemical compound OC1=CC=CC=C1C=NCCN=CC1=CC=CC=C1O VEUMANXWQDHAJV-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- WEKYEFLFIIBFQG-UHFFFAOYSA-N 5-[3-(5-formyl-1h-pyrrol-2-yl)quinoxalin-2-yl]-1h-pyrrole-2-carbaldehyde Chemical compound N1C(C=O)=CC=C1C1=NC2=CC=CC=C2N=C1C1=CC=C(C=O)N1 WEKYEFLFIIBFQG-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- KXLZKGIKVLRMNX-VOMJVXMCSA-A Br[Au]Br.CCOC(=O)CN(C)C1S[Au](Br)(Br)S1.CCOC(=O)CN(C)C1S[Au](Cl)(Cl)S1.CN(C)C1S[Au](Br)(Br)S1.CN(C)C1S[Au](Cl)(Cl)S1.Cl[Au]Cl.[2H]C([2H])[3H].[2H]C([2H])[3H] Chemical compound Br[Au]Br.CCOC(=O)CN(C)C1S[Au](Br)(Br)S1.CCOC(=O)CN(C)C1S[Au](Cl)(Cl)S1.CN(C)C1S[Au](Br)(Br)S1.CN(C)C1S[Au](Cl)(Cl)S1.Cl[Au]Cl.[2H]C([2H])[3H].[2H]C([2H])[3H] KXLZKGIKVLRMNX-VOMJVXMCSA-A 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- GTERMUHKXIVZBY-URYKBLGWSA-G C.C1=CC2=C(C=C1)O[Au]13OC4=C(C=CC=C4)C=N1CCN3=C2.C1=CC=C(C2=C3C=C/C4=C(\C5=CC=CC=C5)C5=N6/C(=C(/C7=CC=CC=C7)C7=CC=C8/C(C9=CC=CC=C9)=C9/C=CC2=N9[Au]6(N87)N34)C=C5)C=C1.CC(C)(C)C1=CC2=N(C=C1)[Au]13N(C2=O)C2=CC(Cl)=C(Cl)C=C2N1C(=O)C1=N3C=CC(C(C)(C)C)=C1.PPCl.[3H][Au].[Cl-].[Cl-].[Cl-] Chemical compound C.C1=CC2=C(C=C1)O[Au]13OC4=C(C=CC=C4)C=N1CCN3=C2.C1=CC=C(C2=C3C=C/C4=C(\C5=CC=CC=C5)C5=N6/C(=C(/C7=CC=CC=C7)C7=CC=C8/C(C9=CC=CC=C9)=C9/C=CC2=N9[Au]6(N87)N34)C=C5)C=C1.CC(C)(C)C1=CC2=N(C=C1)[Au]13N(C2=O)C2=CC(Cl)=C(Cl)C=C2N1C(=O)C1=N3C=CC(C(C)(C)C)=C1.PPCl.[3H][Au].[Cl-].[Cl-].[Cl-] GTERMUHKXIVZBY-URYKBLGWSA-G 0.000 description 1
- WGWVOJCQSNQYIQ-LBBASKNYSA-J C.CC(C)(CN)CN.[Cl-].[Cl-].[H]C(=O)C1=CC=C(C2=C(C3=CC=C(C([H])=O)N3)N=C3C=CC=CC3=N2)N1.[H]C1=N2CC(C)(C)C/N3=C(\[H])C4=CC=C5C6=C(N=C7C=CC=CC7=N6)C6=CC=C1N6[Au]23N54.[H]C1=O[Au]23/O=C(/[H])C4=CC=C(C5=C(N=C6C=CC=CC6=N5)C5=CC=C1N52)N43 Chemical compound C.CC(C)(CN)CN.[Cl-].[Cl-].[H]C(=O)C1=CC=C(C2=C(C3=CC=C(C([H])=O)N3)N=C3C=CC=CC3=N2)N1.[H]C1=N2CC(C)(C)C/N3=C(\[H])C4=CC=C5C6=C(N=C7C=CC=CC7=N6)C6=CC=C1N6[Au]23N54.[H]C1=O[Au]23/O=C(/[H])C4=CC=C(C5=C(N=C6C=CC=CC6=N5)C5=CC=C1N52)N43 WGWVOJCQSNQYIQ-LBBASKNYSA-J 0.000 description 1
- WVUCQOBTMSJZFK-WKVAKUHSSA-N C1=CC2=C(C=C1)N=C1C3=CC=C4/C=N5/CCCCN6=CC7=CC=C(C1=N2)N7[Au]65N43.[CH3-] Chemical compound C1=CC2=C(C=C1)N=C1C3=CC=C4/C=N5/CCCCN6=CC7=CC=C(C1=N2)N7[Au]65N43.[CH3-] WVUCQOBTMSJZFK-WKVAKUHSSA-N 0.000 description 1
- DLPYTAXKBVRHMU-RGCNUTTHSA-N C1=CC2=C(C=C1)N=C1C3=CC=C4/C=N5/CCCN6=CC7=CC=C(C1=N2)N7[Au]65N43.CC1(C)CN2=CC3=CC=C4C5=NC6=C(C=CC=C6)N=C5C5=CC=C6/C=N(/C1)[Au]2(N34)N65.ClC1CN2=CC3=CC=C4C5=NC6=C(C=CC=C6)N=C5C5=CC=C6/C=N(/C1)[Au]2(N34)N65.[CH3-].[CH3-].[CH3-] Chemical compound C1=CC2=C(C=C1)N=C1C3=CC=C4/C=N5/CCCN6=CC7=CC=C(C1=N2)N7[Au]65N43.CC1(C)CN2=CC3=CC=C4C5=NC6=C(C=CC=C6)N=C5C5=CC=C6/C=N(/C1)[Au]2(N34)N65.ClC1CN2=CC3=CC=C4C5=NC6=C(C=CC=C6)N=C5C5=CC=C6/C=N(/C1)[Au]2(N34)N65.[CH3-].[CH3-].[CH3-] DLPYTAXKBVRHMU-RGCNUTTHSA-N 0.000 description 1
- PBFQWNIOAMTZNN-WFYKWJGLSA-N C=1C=CNC=1/C=N/CCC\N=C\C1=CC=CN1 Chemical compound C=1C=CNC=1/C=N/CCC\N=C\C1=CC=CN1 PBFQWNIOAMTZNN-WFYKWJGLSA-N 0.000 description 1
- JKEWKJLOBAOJJX-CKOAPEAFSA-N C=1C=CNC=1\C=N/CC(Cl)C\N=C\C1=CC=CN1 Chemical compound C=1C=CNC=1\C=N/CC(Cl)C\N=C\C1=CC=CN1 JKEWKJLOBAOJJX-CKOAPEAFSA-N 0.000 description 1
- GOEDQUNKWHZNJF-UHFFFAOYSA-N CC(C)(C)C(=O)ONCC(O)CNOC(=O)C(C)(C)C Chemical compound CC(C)(C)C(=O)ONCC(O)CNOC(=O)C(C)(C)C GOEDQUNKWHZNJF-UHFFFAOYSA-N 0.000 description 1
- GMYIPDNKMLKXIL-IKNIIYRSSA-C CC1(C)C2=CC=CC=C2[Au]2(O)N3=CC=CC=C3C3=N2C1=CC=C3.Cl[Au]1(Cl)N2=CC=CC3=C2C2=C(C=CC=N21)C=C3.Cl[Au]1(Cl)N2=CC=CC=C2N=N1C1=CC=CC=C1.Cl[Au]12N3=C(C=CC=C3)C3=CC=CC(=N31)C1=N2C=CC=C1.F[P-](F)(F)(F)(F)F.F[P-](F)(F)(F)(F)F.O[Au]1(O)N2=CC=CC=C2C2=N1C=CC=C2.[Cl-].[Cl-].[H]N1([H])CCN([H])([H])[Au]12N([H])([H])CCN2([H])[H].[H]N1([H])CCN2([H])CCN([H])([H])[Au]12Cl.[H]N12CCCN3([H])CCN4([H])CCCN([H])(CC1)[Au]234 Chemical compound CC1(C)C2=CC=CC=C2[Au]2(O)N3=CC=CC=C3C3=N2C1=CC=C3.Cl[Au]1(Cl)N2=CC=CC3=C2C2=C(C=CC=N21)C=C3.Cl[Au]1(Cl)N2=CC=CC=C2N=N1C1=CC=CC=C1.Cl[Au]12N3=C(C=CC=C3)C3=CC=CC(=N31)C1=N2C=CC=C1.F[P-](F)(F)(F)(F)F.F[P-](F)(F)(F)(F)F.O[Au]1(O)N2=CC=CC=C2C2=N1C=CC=C2.[Cl-].[Cl-].[H]N1([H])CCN([H])([H])[Au]12N([H])([H])CCN2([H])[H].[H]N1([H])CCN2([H])CCN([H])([H])[Au]12Cl.[H]N12CCCN3([H])CCN4([H])CCCN([H])(CC1)[Au]234 GMYIPDNKMLKXIL-IKNIIYRSSA-C 0.000 description 1
- HLAMOBDUIXITIY-UHFFFAOYSA-O CCC(Cl)C[NH3+].[Cl-] Chemical compound CCC(Cl)C[NH3+].[Cl-] HLAMOBDUIXITIY-UHFFFAOYSA-O 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- JVPDLSULMDXURC-HSNVBTBESA-M ClCCl.[Cl-].[H]/C(=N\CCC/N=C(\[H])C1=CC=CN1[H])C1=CC=CN1[H].[H]C1=N2CCCN3=C([H])C4=CC=CN4[Au]23N2C=CC=C12 Chemical compound ClCCl.[Cl-].[H]/C(=N\CCC/N=C(\[H])C1=CC=CN1[H])C1=CC=CN1[H].[H]C1=N2CCCN3=C([H])C4=CC=CN4[Au]23N2C=CC=C12 JVPDLSULMDXURC-HSNVBTBESA-M 0.000 description 1
- SUIUMAFIJUXYNC-UHFFFAOYSA-F Cl[Au]1(Cl)OCC2=CC=CC=N21.N[Au].OCC1=CC=CC=N1[Au](Cl)(Cl)Cl.[Cl-].[H]N1CCN2([H])CCN([H])(CC1)[Au]2(Cl)Cl Chemical compound Cl[Au]1(Cl)OCC2=CC=CC=N21.N[Au].OCC1=CC=CC=N1[Au](Cl)(Cl)Cl.[Cl-].[H]N1CCN2([H])CCN([H])(CC1)[Au]2(Cl)Cl SUIUMAFIJUXYNC-UHFFFAOYSA-F 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000000363 DNA strand passage Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- OSOIDANOLUZQKD-JZORZTFZSA-N F[P-](F)(F)(F)(F)F.[H]C1=N2CC(C)(C)C/N3=C(\[H])C4=C(C)[N-]C=N4[Au]23N2=C[N-]C(C)=C12 Chemical compound F[P-](F)(F)(F)(F)F.[H]C1=N2CC(C)(C)C/N3=C(\[H])C4=C(C)[N-]C=N4[Au]23N2=C[N-]C(C)=C12 OSOIDANOLUZQKD-JZORZTFZSA-N 0.000 description 1
- XGTCZTRZFWXJJR-SOXXGPOESA-N F[P-](F)(F)(F)(F)F.[H]C1=N2CCC/N3=C(\[H])C4=C(C)[N-]C=N4[Au]23N2=C[N-]C(C)=C12 Chemical compound F[P-](F)(F)(F)(F)F.[H]C1=N2CCC/N3=C(\[H])C4=C(C)[N-]C=N4[Au]23N2=C[N-]C(C)=C12 XGTCZTRZFWXJJR-SOXXGPOESA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 230000037060 G2 phase arrest Effects 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 229910020252 KAuCl4 Inorganic materials 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108020003631 Kinetoplast DNA Proteins 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- QSVDMVIPSIBGBX-UHFFFAOYSA-N N1=C(C=CC=C1)N(C=O)C1=NC=CC=C1.[Au+3] Chemical class N1=C(C=CC=C1)N(C=O)C1=NC=CC=C1.[Au+3] QSVDMVIPSIBGBX-UHFFFAOYSA-N 0.000 description 1
- BKGSBPGCKHCMLV-MFQOAVFDSA-N N1C=NC(\C=N\CC(C)(C)C\N=C\C2=C(NC=N2)C)=C1C Chemical compound N1C=NC(\C=N\CC(C)(C)C\N=C\C2=C(NC=N2)C)=C1C BKGSBPGCKHCMLV-MFQOAVFDSA-N 0.000 description 1
- ZDYDAPFJCDYUAX-MKFXEVHTSA-N N1C=NC(\C=N\CCC\N=C\C2=C(NC=N2)C)=C1C Chemical compound N1C=NC(\C=N\CCC\N=C\C2=C(NC=N2)C)=C1C ZDYDAPFJCDYUAX-MKFXEVHTSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229910019032 PtCl2 Inorganic materials 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical class [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- HOKFHGVPVPIUEN-UHFFFAOYSA-N [Au+3].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical class [Au+3].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 HOKFHGVPVPIUEN-UHFFFAOYSA-N 0.000 description 1
- MOFINMJRLYEONQ-UHFFFAOYSA-N [N].C=1C=CNC=1 Chemical group [N].C=1C=CNC=1 MOFINMJRLYEONQ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- HYOCSVGEQMCOGE-UHFFFAOYSA-N hydron;propane-1,3-diamine;dichloride Chemical class Cl.Cl.NCCCN HYOCSVGEQMCOGE-UHFFFAOYSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 125000000879 imine group Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000010671 solid-state reaction Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/12—Gold compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G7/00—Compounds of gold
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
- C07C209/14—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups
- C07C209/16—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
- C07C209/86—Separation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/06—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton from hydroxy amines by reactions involving the etherification or esterification of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
Definitions
- THIS INVENTION relates to novel chemotherapeutic agents. It relates in particular to novel bis(pyrrolide-imine) and bis(imidazolato-imine) gold(III) Schiff base complexes as chemotherapeutic agents.
- Au(I) is a soft d 10 metal ion.
- the most common coordination geometry for gold(I) complexes is linear, with the molecules usually consisting of a central gold(I) ion coordinated by either phosphorous or sulfur donor ligands.
- Au(I) complexes undergo facile ligand exchange in aqueous solutions, with the rate of ligand exchange increasing in the order R 3 P ⁇ RS ⁇ ⁇ X ⁇ .
- Au(I) antiarthritic compounds contributes to both the therapeutic activity of Au(I) antiarthritic compounds and the side effects observed with these drugs. 4
- Auranofin Scheme 1 which is widely used in the treatment of rheumatoid arthritis.
- Auranofin and its many derivatives have also become the focus of research into gold(I) based anti-cancer agents.
- Several complexes have been found to exhibit cytotoxicity greater than that of cisplatin against melanoma and leukemia cancer cell lines in particular. 5
- the in vitro test results of many gold(I) chelates against various human cancer cell lines have been promising. 4,5
- Cisplatin is still widely used today in the treatment of several types of tumors, particularly testicular cancer. Its use is, however, hindered by some clinical problems such as a severe toxicity towards non-cancerous tissue and the frequent occurrence of initial and acquired resistance to the treatment. 6 The most concerning adverse side effect is nephrotoxicity correlated to platinum binding and inactivation of renal thiol-containing enzymes. 6
- gold(III) as an anti-tumor agent is that it has a d 8 electron configuration, with vacant d(x 2 -y 2 ) orbitals, and therefore adopts a rigorously square planar coordination geometry. Gold(III) is therefore isostructural and isoelectronic to platinum(II). 8 Despite the similarity to platinum(II) literature relating to the use of gold(III) as a chemotherapeutic agent is scarce. 6 The rarity of data on gold(III) complexes probably derives from their high redox potential and relatively poor stability, which make their use rather problematic under physiological conditions.
- the gold(III) ion can be readily reduced to the more stable gold(I) ion or even metallic gold(0) under the in vivo reducing conditions, characteristic of the mammalian environment.
- the coordination of a ligand, which is a strong ⁇ -donor and ⁇ -acceptor ligand that can stabilize the gold(III) ion under physiological conditions is therefore critical if gold(III) is to be used in the treatment of cancer.
- the gold(III) complexes with multidentate N-donor ligands [Au(phen)Cl 2 ]Cl, [Au(terpy)Cl]Cl 2 , [AuCl(dien)]Cl 2 , [Au(cyclam)](ClO 4 ) 2 Cl and [Au(en) 2 ]Cl 2 , showed reasonable stability in physiological buffer solutions at 37° C.
- These gold(III) complexes have been greatly stabilized by the chelation of the gold(III) ion to polyamine ligands. This stabilization was evidenced by measurements of the reduction potentials of the complexes. 8,10 The stabilization was less evident for the less basic phenanthrene and terpyridine ligands.
- the gold(III) dithiocarbamate complexes are examples of gold(III) chelates with Au—S bond which are bound to ligands through a sulfur atom. Examples of dithiocarbamate complexes that have been screened against various cancer cell lines are shown below in Scheme 3.
- the Gold(III) dithiocarbamate complexes that have been screened against various human cancer cell lines exhibited greater cytotoxic effects compared to cisplatin.
- the complexes were also bioactive against drug resistant cancer cell lines and induced apoptosis. 6,7
- the compounds have proven to be stabile under physiological conditions and readily bind to calf thymus DNA, inhibiting both DNA and RNA synthesis. Experiments on red blood cells indicated that haemolytic properties might contribute significantly to the bioactivity of the agents.
- the complexes triggered cancer cell death via apoptotic and non-apoptotic pathways and affected mitochondrial functions.
- the gold(III) chelates of this invention have tetradentate dianion ligands. More specifically they are N 2 N′ 2 tetradentate ligands and therefore are closely related to the highly cytotoxic gold(III) tetraarylporphyrins.
- the advantage of tetradentate ligands is that they are better able to stabilize the gold(III) cation against reduction under physiological conditions and are therefore potentially more useful as drugs. 5,9 Coordination of a tetradentate dianionic ligand to gold(III) gives a mono-cationic gold(III) compound having a planar geometry.
- the gold(III) porphyrins have proven to be stable under physiological conditions.
- the complexes [Au(dcbpb)]Cl and [Au(salen)]Cl show signs of slow decomposition under similar conditions.
- 13 [Au(TPP)]Cl has displayed promising anticancer activities toward a panel of human cancer cell lines including nasopharyngeal carcinoma, promyelocytic leukaemia, hepatocellular carcinoma, cervical epithelioid carcinoma, and oral epidermoid carcinoma. 13
- the IC 50 values of [Au(TPP)]Cl ranged between 0.11 and 0.73 ⁇ M.
- IC 50 values show that [Au(TPP)]Cl is several hundred times more cytotoxic than cisplatin.
- This compound also shows significant cytotoxicity against KB-3-1 and its multi-drug resistant (KB-V1) variant.
- KB-V1 multi-drug resistant
- the latter possesses a high level of membrane P-glycoproteins, which exclude drugs such as vinblastine and doxorubicin. 13
- PBMCs peripheral blood mononuclear cells
- CCD-19Lu cells which is a fibroblast cell line derived from normal lung tissue
- Results by MTT assay revealed that [Au(TPP)]Cl exhibits at least ten-fold higher cytotoxicity to cancer cells than non-cancerous cells. 13
- the presence of gold(III) ions has been proven to be critical for the observed in vitro chemotherapeutic properties. This conclusion is based on the inactivity of [Zn II (TPP)].
- the zinc(II) analogue of [Au(TPP)]Cl exhibits an IC 50 value greater than 50 ⁇ M.
- the gold(III) ion is unstable under physiological conditions as it undergoes reduction to colloidal gold.
- porphyrin ligand is, however able to stabilize the gold(III) ion and it is hypothesized that [Au(TPP)] + acts as a stable lipophilic planar cation for binding to bio-molecular target(s) through non-covalent interactions.
- Apoptosis is characterized by an ordered series of biochemical and biophysical reactions that are regulated by various genes, this is in contrast to necrosis which is premature cell death. While apoptosis often provides beneficial effects to the organism, necrosis is almost always detrimental, and can be fatal. Apoptosis does not trigger inflammatory tissue reactions, and thus is advantageous for cytotoxic chemotherapeutic agents to be able to induce apoptotic cell death as opposed to necrosis.
- the compound [Au(TPP)]Cl induced cytotoxicity in NPC cells via an apoptotic pathway.
- Tetradentate Schiff base ligands comprising two pyrrole groups bridged by a synthetically variable di(azomethine) unit have been known for several decades. 14 However, studies of both the free base ligands as well as their metal chelates are quite limited. 14 Coordination of this class of ligands to a metal cation usually occurs with the concomitant deprotonation of the pyrrole NH groups, this means that they are N 2 N′ 2 tetradentate, dianionic ligands. The ligands have been previously bound to Ru(II), Pd(II), Ni(II), Co(III), Mn(II), Sm(II), Pt(II) and Fe(III).
- the free base bis(pyrrole-imine) compounds have been shown to exhibit spectacular supramolecular structures both with aromatic 24 and alkyl 14 bridges.
- the pyrrole N—H and imine type nitrogen atoms form a highly predictable hydrogen bonding motif.
- the compounds with aromatic bridges have even been used to form distinct nanostructures, with the effect of isomeric molecules being examined in an attempt to try and further understand the self assembly of organic molecules into distinct nanostructures.
- the present invention provides new classes of gold(III) bis(pyrrolide-imine) and bis(imidazolato-imine) compounds.
- Several of these compounds have been shown to be cytotoxic towards a wide range of human cancer cell lines having an activity similar to, or better than, cisplatin which is currently the industry standard.
- W is independently selected from W 1 , W 2 , W 3 , W 4 , W 5 ,
- Y is Y 1
- Y represents a pair of substituents independently selected from H, C 1 -C 6 alkyl, Z 5 or Z 6 aryl,
- Y is optionally a bridging structure that may comprise one or more C 1 -C 6 amide, C 1 -C 6 ether, or C 1 -C 6 ester groups,
- R-R 39 are independently selected from no substituent, a lone pair of electrons, H, halogen, C 5 -C 6 aryl, C 1 -C 12 alkyl, amine, C 1 -C 6 alkylamine, C 1 -C 6 amide, nitro, cyano, carboxyl, C 1 -C 6 ester, phosphane, thiol, C 1 -C 6 thioether, OR 40 , and suitable pairs of adjacent R groups (R-R 39 ) may optionally together form part of a C 5 or C 6 aryl ring, a Z 5 or Z 6 ring,
- R 40 is independently selected from H, C 1 -C 6 alkyl, Z 5 or Z 6 aryl, C 1 -C 6 ester, poly(—C 2 O—), amine, and C 1 -C 6 alkylamine,
- Z-Z 24 are independently selected from C, N, P, O, and S, and
- X ⁇ is a pharmaceutically acceptable anion.
- the anion X ⁇ may be selected from halide, hexafluorophosphate, nitrate, and triflate.
- Examples of representative structurally characterized and tested compounds of the invention are the following compounds.
- Schemes 5a, 5b, and 5c show, by way of illustration of the parent derivatives of each new class of gold(III) chelates, partially labeled thermal ellipsoid diagrams of the X-ray crystal structures of MA_AuPr (compound 1.1a), KA_AumacroPr (compound 1.1Y 1 a), and KA_AuMeImPr (compound 1.1f), respectively.
- MA_AuPr (1.1a) has several advantages over currently available inorganic chemotherapeutic agents in clinical use. Firstly, the synthesis of the ligands belonging to the 1.1a-1.1f series of compounds is a simple one-pot reaction, requiring minimal purification. Chelation of the ligand to gold(III) is simple and gives a clean easily re-crystallized product. Derivatization of the parent ligand was found to be possible and different derivatives showed varying activity, suggesting that there is a structure/activity relationship between the different derivatives. In vitro testing showed that the chelate 1.1a was more effective than cisplatin against ca. 25% of the 60 human cancer cell lines against which it was tested. The in vitro mechanism of action of the drug has been established and is highly specific. This indicates that the activity of the drug can be carefully controlled.
- W is independently selected from W 1 , W 2 , W 3 , W 4 , W 5 ,
- Y is Y 1
- Y represents a pair of substituents independently selected from H, C 1 -C 6 alkyl, Z 5 or Z 6 aryl,
- Y is optionally a bridging structure that may comprise one or more C 1 -C 6 amide, C 1 -C 6 ether, or C 1 -C 6 ester groups,
- R-R 39 are independently selected from no substituent, a lone pair of electrons, H, halogen, C 5 -C 6 aryl, C 1 -C 12 alkyl, amine, C 1 -C 6 alkylamine, C 1 -C 6 amide, nitro, cyano, carboxyl, C 1 -C 6 ester, phosphane, thiol, C 1 -C 6 thioether, OR 40 , and suitable pairs of adjacent R groups (R-R 39 ) may optionally together form part of a C 5 or C 6 aryl ring, a Z 5 or Z 6 ring,
- R 40 is independently selected from H, C 1 -C 6 alkyl, Z 5 or Z 6 aryl, C 1 -C 6 ester, poly(—C 2 O—), amine, and C 1 -C 6 alkylamine,
- Z-Z 24 are independently selected from C, N, P, O, and S, and
- X ⁇ is a pharmaceutically acceptable anion for the treatment of cancer.
- the anion X ⁇ may be selected from halide, hexafluorophosphate, nitrate, and triflate.
- composition including at least one compound selected from compounds of the Formula (I),
- W is independently selected from W 1 , W 2 , W 3 , W 4 , W 5 ,
- Y is Y 1
- Y represents a pair of substituents independently selected from H, C 1 -C 6 alkyl, Z 5 or Z 6 aryl,
- Y is optionally a bridging structure that may comprise one or more C 1 -C 6 amide, C 1 -C 6 ether, or C 1 -C 6 ester groups,
- R-R 39 are independently selected from no substituent, a lone pair of electrons, H, halogen, C 5 -C 6 aryl, C 1 -C 12 alkyl, amine, C 1 -C 6 alkylamine, C 1 -C 6 amide, nitro, cyano, carboxyl, C 1 -C 6 ester, phosphane, thiol, C 1 -C 6 thioether, OR 40 , and suitable pairs of adjacent R groups (R-R 39 ) may optionally together form part of a C 5 or C 6 aryl ring, a Z 5 or Z 6 ring,
- R 40 is independently selected from H, C 1 -C 6 alkyl, Z 5 or Z 6 aryl, C 1 -C 6 ester, poly(—C 2 O—), amine, and C 1 -C 6 alkylamine,
- Z-Z 24 are independently selected from C, N, P, O, and S, and
- X ⁇ is a pharmaceutically acceptable anion.
- the anion X ⁇ may be selected from halide, hexafluorophosphate, nitrate, and triflate.
- the pharmaceutical composition may be for use in the treatment of cancer.
- a method of treating cancer including the step of administering, to a subject in need of treatment, a pharmaceutically effective amount of at least one compound selected from compounds of Formula (I),
- W is independently selected from W 1 , W 2 , W 3 , W 4 , W 5 ,
- Y is Y 1
- Y represents a pair of substituents independently selected from H, C 1 -C 6 alkyl, Z 5 or Z 6 aryl,
- Y is optionally a bridging structure that may comprise one or more C 1 -C 6 amide, C 1 -C 6 ether, or C 1 -C 6 ester groups,
- R-R 39 are independently selected from no substituent, a lone pair of electrons, H, halogen, C 5 -C 6 aryl, C 1 -C 12 alkyl, amine, C 1 -C 6 alkylamine, C 1 -C 6 amide, nitro, cyano, carboxyl, C 1 -C 6 ester, phosphane, thiol, C 1 -C 6 thioether, OR 40 , and suitable pairs of adjacent R groups (R-R 39 ) may optionally together form part of a C 5 or C 6 aryl ring, a Z 5 or Z 6 ring,
- R 40 is independently selected from H, C 1 -C 6 alkyl, Z 5 or Z 6 aryl, C 1 -C 6 ester, poly(—C 2 O—), amine, and C 1 -C 6 alkylamine,
- Z-Z 24 are independently selected from C, N, P, O, and S, and
- X ⁇ is a pharmaceutically acceptable anion.
- the anion X ⁇ may be selected from halide, hexafluorophosphate, nitrate, and triflate.
- a compound selected from compounds of Formula (I) has hereinbefore described in the manufacture of a medicament for the treatment of cancer.
- the invention described thus provides a new class of gold(III) bis(pyrrolide-imine) and bis(imidazolato-imine) Schiff base complexes for use as novel anticancer chemotherapeutic agents.
- These complexes consist of a central gold(III) ion chelated by a N 2 N′ 2 tetradentate bis(N-heterocycle-imine) type ligand.
- N—H groups Upon coordination of the gold(III) ion, the two pyrrole-type nitrogen atoms (N—H groups) are deprotonated, giving the ligand an overall charge of ⁇ 2.
- the metal ion complex therefore has an overall charge of +1; hence the chelates are associated with an anion.
- the complexes were designed to be predominantly planar which allows the gold(III) chelates to intercalate between DNA base pairs.
- the overall charge on the cation allows for favorable electrostatic interactions with the negatively charged phosphate backbone of the DNA double helix.
- the molecular target for the gold(III) complexes is thus DNA (and possibly also related nucleotides).
- Compound 1.1a acts as a topoisomerase II poison at low concentrations and an inhibitor of the enzyme at high concentrations (topoisomerase II is critical for cell replication, being responsible for the decatenation of daughter chromatids during mitosis).
- Compound 1.1Y 1 a (KA_AumacroPr), on the other hand, acts as a catalytic inhibitor of both topoisomerase I and topoisomerase II.
- the gold(III) chelates of the invention are novel in design and structure and their mode of synthesis is novel.
- the complexes are readily crystallized, easily purified, and have been fully characterized.
- the complexes exhibit a highly specific mode of action (all of the compounds target topoisomerase II and some also target topoisomerase I).
- the mechanism of action has been proven to be dependent on the presence of the gold(III) ion since the metal-free complexes are inactive.
- Y may represent two hydrogen atoms or Y 1 .
- Y may be Y 1
- Z 19 and Z 24 may be N.
- Z 20 -Z 23 may be C.
- the groups R-R 5 may be selected from H, C 1 -C 3 alkyl, O—C 1 -C 3 alkyl, hydroxyl and halogen.
- the C 1 -C 3 alkyl group may be a methyl group
- the O—C 1 -C 3 alkyl group may be an O-ethyl group
- the halogen may be chlorine.
- W may be selected from W 1 , W 2 , W 3 or W 4 .
- the groups R 6 -R 27 may then be selected from H, C 1 -C 3 alkyl, O—C 1 -C 3 alkyl and halogen.
- the C 1 -C 3 alkyl group may be a methyl group
- the O—C 1 -C 3 alkyl may be an O-ethyl group
- the halogen may be chlorine.
- More preferred compounds are compounds selected from:
- the invention extends further to a pharmaceutical composition comprising at least one compound as hereinbefore described.
- the invention extends to a method of preparing a compound of Formula (I), which includes the steps of condensing a diamine of the general formula A
- the invention extends further to a method of preparing a compound of general Formula (I), which includes the step of reacting a carbonyl compound of the general formula D
- the tetraalkylammonium tetrahaloaurate(III) may be tetrabutylammonium tetrachloroaurate(III).
- the butyl group may be a t-butyl group.
- the method may include reacting the diamine with the tetraalkylammonium tetrahaloaurate (III) in the presence of a salt selected from halides, hexafluorophosphates, nitrates, and triflates to produce the corresponding compound of Formula (I) in which k is the corresponding anion.
- the salt may be a tetraalkylammonium hexafluorophosphate such as tetra-t-butylammonium hexafluorophosphate.
- the method may include the further step of reacting the compound of Formula (I) in which X ⁇ is chloride with a salt selected from halides other than chloride, hexafluorophosphates, nitrates, and triflates to produce a compound of Formula (I) in which X ⁇ is the anion of the said salt.
- the invention extends to a method of preparing a 2-substituted 1,3-diamine intermediate of the general formula A 1
- the invention extends to bis(pyrrole-imine) ligands selected from:
- the invention extends further to a method for the preparation of tetrabutylammonium tetrachloroaurate, [Bu 4 N][AuCl 4 ], the method including the step of extracting [Bu 4 N][AuCl 4 ] from a mixture using an organic solvent-extraction purification step to produce an acid-free, crystalline [Bu 4 N][AuCl 4 ].
- the method may include reacting an aqueous solution of H[AuCl 4 ] and [Bu 4 N][HSO 4 ] to produce the mixture and extracting the [Bu 4 N][AuCl 4 ] from the mixture with the organic solvent.
- Scheme 6a Single-dose screening results for MA_AuPr over 60 human cancer cell lines. A negative growth percent is favorable and shows up as a positive bar on the graph.
- Scheme 6b Single-dose screening results for KA_AumacroPr over 60 human cancer cell lines. A negative growth percent is favorable and shows up as a positive bar on the graph.
- Scheme 6c Single-dose screening results for KA_AuMelmPr over 60 human cancer cell lines. A negative growth percent is favorable and shows up as a positive bar on the graph.
- Scheme 12 EB gel showing the poisoning at low concentrations (0.5 ⁇ M) and catalytic inhibition at higher concentrations (50 ⁇ M) of topoisomerase II activity on supercoiled plasmid DNA substrate by MA_AuPr.
- Scheme 13 EB gel showing the inactivity of MA_AuPr against topoisomerase I compared to the chemotherapeutic agent CPT (camptothecin), which is specifically a topoisomerase I poison.
- Scheme 14 EB gel showing the inactivity of MA_H2PrLig (the metal-free ligand) against topoisomerase II compared to the chemotherapeutic agent VP-16 (etoposide), which is specifically a topoisomerase II poison. There is evidence of weak DNA-cleavage induction in the presence of topoisomerase II from the free ligand at 500 ⁇ M concentration.
- Scheme 15 EB gel showing the diminished activity of MA_PdPr (the Pd 2+ analogue of MA_AuPr) against topoisomerase II compared to the chemotherapeutic agent VP-16 (etoposide), which is specifically a topoisomerase I poison. There is evidence of DNA-cleavage induction in the presence of topoisomerase II at 50 ⁇ M concentration (a 100-fold weaker effect than the gold(III) complex).
- Scheme 16 Top: agarose gel electrophoresis topoisomerase II (topo II) DNA cleavage assay (66 ng kinetoplast DNA, 4 U topo II) as a function of the concentration of KA_AumacroPr (complex 1.1Y 1 a). Lanes 1-4 contain catenated DNA (no topo II), decatenated DNA (topo II present), decatenated DNA (solvent control), and linear DNA, respectively. The lane marked VP-16 contained DNA, topo II, and etoposide (VP-16). Band labels: I, catenated DNA; II, open-circular (OC) DNA; III, linear DNA; IV, closed-covalently circular (CCC) DNA.
- Lanes 5-13 included compound 1.1Y 1 a from 5 nM to 500 nM in 10-fold concentration increments, respectively.
- Scheme 17 Inhibition of human topoisomerase/by KA_AumacroPr as determined by supercoiled plasmid DNA relaxation assay (agarose gel electrophoresis). Lanes 2-12 have 5U of topoisomerase I. The enzyme fully relaxes supercoiled (SC) DNA in lanes 3-8 for KA_AumacroPr concentrations ranging from 0-50 nM. At concentrations from 500 nM- 500 ⁇ M, topoisomerase I exhibits abnormal and incomplete substrate relaxation.
- SC supercoiled
- the gold(III) complexes of this invention were screened by the National Cancer Institute (NCI, USA) against their panel of 60 different human cancer cell lines. These screens initially entail a one-dose test for the compound at a high concentration (10 ⁇ M; e.g. Schemes 6a-6c). Compounds with a good cytotoxicity profile in the one-dose screen are then subjected to a five-dose screen for the full panel of sixty human cancer cell lines (the so-called 5-dose NCI-60 screen). In the full five-dose screen, the compound concentration is varied in five doses from 10 ⁇ 8 M to 10 ⁇ 4 M in order to establish a dose-response function of percentage cell growth versus the concentration of the test agent.
- NCI National Cancer Institute
- Scheme 8a Dose-response curves for three commercial anticancer drugs (cisplatin, mitomycin, camptothecin) and three Au(III) chelates are shown in Scheme 8a. The more abrupt the curve, the harder the dose-response function.
- Scheme 8b shows dose-response curves obtained with HeLa cells incubated with the macrocydic gold(III) complexes 1.1Y 1 a, 1.1Y 1 b, and 1.5Y 1 a at 37° C.
- complex 1.5Y 1 a has very good cytotoxicity with a sub-micromolar IC 50 value of 370 nM; complexes 1.1Y 1 a and 1.1Y 1 b were also cytotoxic and had IC 50 values of ca. 3 ⁇ M.
- the mean cytotoxicity data summarized in Scheme 7 were compiled over 60 human cancer cell lines from the NCI database.
- the experimental parameters GI 50 , IC 50 , and LC 50 are mean concentrations at which 50% growth inhibition, 100% (total) growth inhibition, and 50% cell death occur, respectively.
- the data show that MA_AuPr is somewhat more cytotoxic than cisplatin and carboplatin when comparing the IC 50 and
- the dose-response curves for the bis(pyrrolide-imine) chelates of the invention are steeper, or harder, than those of all the compounds compared in Scheme 7. Of the other drugs shown, only mitomycin (a powerful organic DNA alkylating and cross-linking agent) exhibits a comparably steep mean dose-response function.
- MA_AuPr has a lower LC 50 value than the other Pt(II) and Au(III) compounds and a comparable LC 50 value to camptothecin (a potent topoisomerase I poison).
- MA_AuPr has a better IC50 value than cisplatin and carboplatin.
- the hard dose-response function of MA_AuPr means that the therapeutic dose in vitro has a narrow window. Thus, 50% growth inhibition, on average, requires a relatively high concentration of the compound (7 ⁇ M).
- the three Au(III) macrocycles developed and tested to date exhibit the best cytotoxicity of all the compounds examined (at least in the HeLa cell line) with softer dose-response profiles more akin to commercial natural product drugs like camptothecin.
- the GI 50 values for the three compounds 1.1Y 1 a, 1.1Y 1 b, and 1.5Y 1 a are all around 100 nM.
- Complex 1.5Y 1 a has a particularly attractive dose-response profile that is better than that of camptothecin (Scheme 8a) because the LC 50 value is ⁇ 10 ⁇ M (i.e. about one-third of camptothecin's LC 50 value).
- Scheme 9 shows a plot of ⁇ log(GI 50 /M) for MA_AuPr versus the equivalent data for cisplatin.
- the plot in Scheme 9 shows that, on average, the chelate MA_AuPr exhibits 95% of the growth inhibition activity of cisplatin.
- the region marked A on the plot accounts for ca. 25% of the cancer cell lines tested and confirms that a sizeable fraction of cancer cell lines are either equivalently susceptible or significantly more susceptible to MA_AuPr than to cisplatin.
- the complex MA_AuDM shows a similar activity profile to that of MA_AuPr (with 91% of the activity of cisplatin on average and around 12% of the cell lines being more susceptible to this Au(III) drug than to cisplatin).
- Scheme 10a shows a comparison of ⁇ log(GI 50 ) values for MA_AuPr (the best performing open-chelate Au(III) complex of this invention) with two comparable commercially available anticancer drugs (cisplatin and mitomycin) for selected human cancer cell lines (LE, leukemia; LC, lung cancer; CO, colo-rectal cancer; RE, renal carcinoma; PR, prostate cancer; BR, breast cancer).
- MA_AuPr the best performing open-chelate Au(III) complex of this invention
- Scheme 10b compares the performance (specifically as the drug concentration at which 50% growth inhibition is observed) of two open-chelate gold(III) complexes of the invention with existing commercial anti-cancer drugs for selected human cancer cell lines.
- the average ⁇ log(GI 50 ) values for all of the drugs over the cancer cell lines plotted are marked with an asterisk.
- MA_AuPr is more active than MA_AuDM and cisplatin for the cancer cell lines plotted.
- MA_AuPr also performs similarly to mitomycin for several important cancers (renal carcinoma and colon cancer) and is better than cisplatin, on average, for the selected leukemia, colon, and renal cancer cell lines.
- MA_AuPr is less active than the topoisomerase poisons camptothecin (topo I) and daunorubicin (topo II).
- potent topoisomerase poisons are acutely toxic with some severe side-effects. This is often problematic because the damage caused to healthy cell DNA by these drugs is mutagenic and has been shown to result in the initiation of secondary cancer post-treatment (i.e. genotoxicity).
- the current strategy employed by oncologists is therefore to administer a potent topoisomerase poison (camptothecin or daunorubicin) and an independent topoisomerase catalytic inhibitor to diminish the damage caused by these highly cytotoxic topoisomerase poisons.
- the compound MA_AuPr is an effective cytotoxic agent that is suitably active against multiple human cancer cell lines. Identification of the cellular target of the compound and elucidation of its biological mechanism of action are critical to the optimization of lead compounds into successful chemotherapeutic agents. There are three key parameters which define the cytotoxic activity of a compound against a given cancer cell line, namely its GI 50 , IC 50 , and LC 50 values (see Scheme 8a).
- One drug tested over 60 cancer cell lines affords 180 experimental data that may be compared with the same parameters for all other compounds similarly tested against the NCI's panel of 60 human cancer cell lines. Only hierarchical cluster analysis offers a tractable statistical approach to establish functional relationships between drugs with a large data set.
- Scheme 11 shows a dendrogram obtained via hierarchical cluster analysis of the GI 50 , IC 50 , and LC 50 values for a range of commercial anti-cancer drugs with known mechanisms of action.
- the Au(III) compounds of the invention were included in the analysis and are highlighted in red. It is clear from the clusters shown that the activity of MA_AuPr correlates best with that of etoposide, one of the most widely used topoisomerase II poisons. The compound also appears on a branch with a direct, though distant, link to the drugs daunorubicin and cisplatin.
- Daunorubicin is a potent topoisomerase II poison, while cisplatin has been shown to be an effective catalytic inhibitor 25 of topoisomerase II (in addition to its role as a DNA cross-linker and guanine-N7 “alkylating” agent).
- Topoisomerase II is an essential nuclear enzyme found in all living cells. Topoisomerase II participates in various DNA metabolic processes, such as transcription, DNA replication, chromosome condensation, and de-condensation, and is essential at the time of chromosome segregation after cell division. 26 This enzyme transiently creates a protein-concealed double-strand break in one DNA molecule through which a second double-stranded DNA molecule can be transported prior to religation of the DNA. 26 There are two classes of compounds that act against topoisomerase II—poisons and catalytic inhibitors.
- the former compounds stabilize the ternary drug-enzyme-DNA cleavage complex and favor an increase in the number of DNA double strand breaks; these are highly damaging to cancer cells and lead to apoptosis (programmed cell death).
- the latter compounds are either competitive inhibitors (block DNA binding), non-specific inhibitors (react with topoisomerase II sulfhydryl groups, e.g., cisplatin, 25 thereby altering the proper function of the enzyme), or inhibitors that block the ATPase domain of the enzyme (effectively curtailing the ATP-dependent DNA strand passage step in the cycle).
- topoisomerase II Highly successful, though highly toxic, commercial anticancer compounds active against topoisomerase II include the drugs etoposide, teniposide, doxorubicin, daunorubicin, and idarubicin. 26 There are, however, difficulties associated with the use of these drugs in chemotherapy due to their high general toxicity.
- the cardiac toxicity of the compounds is generally high and catalytic inhibitors of topoisomerase II (such as dexrazoxane, ICRF-187) are administered along with a topoisomerase poison to temper the toxicity of the poison, 28 or to prevent tissue damage (necrosis) when extravasation of a topoisomerase poison occurs during chemotherapy. 29 There is also good evidence to suggest that topoisomerase poisons are themselves carcinogenic, such that the development of post-treatment (secondary) cancer occurs in some patients. 30
- the compound MA_AuPr clearly targets topoisomerase II if the statistical analysis of the NCI data for a range of drugs shown in Scheme 11 is correct.
- MA_AuPr was therefore assayed for its action against topoisomerase II in vitro using TopoGEN's standard protocol over a wide range of test agent concentrations (0.005 to 500 ⁇ M) in order to obtain direct experimental proof for the apparent cellular target of the compound to ensure that a fundamental understanding of the mechanism of action of this new class of Au(III) compounds exists.
- TopoGEN and at the University of Central Florida.
- the DNA cleavage experiments were performed in vitro using purified topoisomerase I and II enzymes and supercoiled plasmid DNA as the substrate.
- the controls that were used in the experiment were linear marker DNA as well as reactions without the gold(III) complex and high concentrations of VP16.
- the compound VP16 (etoposide) is a commercially available DNA intercalator chemotherapeutic agent, widely used in the treatment of lung and testicular cancers as well as lymphomas.
- the choice of VP16 as a control is based on the fact that it is a poor topoisomerase II inhibitor, but is a powerful topoisomerase II poison which arrests the enzyme's cycle at the ternary drug-enzyme-DNA cleavage complex stage, leading to observation of linear DNA fragments upon SDS denaturation of the enzyme (i.e., work-up).
- Comparison of the VP16 results with the results of MA_AuPr would therefore give a good indication of whether the gold(III) chelate is an inhibitor or a poison.
- the results of the ethidium bromide (EB) gel analysis are shown in Scheme 12.
- Lane 1 of the gel is the control experiment with only supercoiled plasmid DNA present.
- the control contains no topoisomerase II and so the DNA supercoiled structure cannot be relaxed, as the topoisomerase II enzyme would usually do.
- the gel shows that the complex MA_AuPr begins to effectively poison topoisomerase II at a concentration of 0.5 ⁇ M (lane 5 of the gel), as evidenced by the formation, trapping, and detection of linear DNA cleavage products at this concentration of the test agent.
- a higher concentration of the test agent 50 ⁇ M
- both supercoiled plasmid DNA and linear cleavage products are observed.
- MA_AuPr exhibits dual action at this concentration in that it functions both as a topoisomerase II poison (forming linear DNA) and as a topoisomerase II catalytic inhibitor (preventing relaxation of the supercoiled plasmid DNA substrate).
- MA_AuPr behaves exclusively as a catalytic inhibitor of the enzyme.
- MA_AuPr was also tested to determine if the compound was a topoisomerase I poison or inhibitor since the compound appears to be a topoisomerase II-specific agent and not a DNA intercalator with multiple enzyme targets.
- the results are shown in the EB gel in Scheme 13.
- the gel electrophoresis experiment shows that the gold(III) chelate is not a topoisomerase I poison. This conclusion is based on comparison of the migration of the DNA with various concentrations of the gold(III) chelate with the lane containing CPT (camptothecin, a topoisomerase-I specific poison) and linear DNA as a reference or marker. This result shows that the gold(III) chelate specifically poisons topoisomerase II and not topoisomerase I.
- the role of gold(III) in the efficacy of the compound was determined by modifying the structure of MA_AuPr by replacing the Au(III) cation with Pd(II) to afford MA_PdPr (the isoelectronic square planar coordination complex of known structure and geometry 31 ) and carrying out the DNA relaxation assay with topoisomerase II as before.
- the metal-free ligand (MA_H2PrLig) was tested under identical conditions to confirm that the mechanism of action is related to the intact structure of the metal chelate. The results are shown in Schemes 14 and 15.
- the efficacy of the Au(III) chelate is 100 times higher than that of the isoelectronic Pd(II) chelate. This result is expected and is consistent with the electrophilic character of the Au(III) ion, which is known to favor electrostatic interactions with aromatic groups or anions perpendicular to the square planar coordination group (i.e., the vacant axial interaction sites at the metal center).
- Compound 1a is also positively charged, whereas the Pd(II) chelate is neutral and thus likely to exhibit diminished electrostatic attraction for the phosphate backbone of double-stranded DNA.
- topo II inhibition assay for the Au(III) macrocycle KA_AumacroPr is shown above in Scheme 16.
- this complex functions as a pure catalytic inhibitor of topo II since no trapped linear DNA cleavage products are evident that would signal behavior of the complex as a topo II poison.
- the enzyme inhibition is characterized by an IC 50 of 4.8 ⁇ M, which is in excellent agreement with the cell cytotoxicity IC 50 value measured for this compound against HeLa cells (Scheme 8b).
- the test agent KA_AumacroPr interferes with the normal operation of human topoisomerase I. Specifically, abnormal relaxation products are generated from supercoiled plasmid DNA. This is consistent with strong intercalative binding of KA_AumacroPr to the plasmid DNA probably before and after the action of topoisomerase I, and consequently inhibition of its normal turnover cycle.
- the macrocyclic Au(III) complex 1.1Y 1 b functions as a catalytic inhibitor of human topoisomerase I. Similar data were obtained for complexes 1.1Y 1 a and 1.5Y 1 a.
- a drug to act as a topoisomerase II poison two molecular recognition events must occur. Firstly, the drug must bind to DNA via intercalation between base pairs and secondly, the drug must interact with topoisomerase II in such a way that religation of the DNA after formation the topoisomerase II-DNA covalent complex (the catalytic intermediate) is impossible. The enzyme is poisoned at this point and the cycle irreversibly disrupted by the drug.
- Scheme 18 shows titration data for the titration of complex 1.1 a with calf-thymus DNA (ctDNA).
- [DNA] is the concentration of DNA base pairs
- ⁇ a is the extinction coefficient (A abs /[M]) observed for the 383-nm MLCT absorption band of MA_AuPr at a given DNA concentration
- ⁇ f and ⁇ b are the extinction coefficient for the free Au(III) complex and the extinction coefficient for the Au(III) complex in the fully bound form, respectively.
- K a is the equilibrium binding constant in M ⁇ 1
- Ct is the total Au(III) complex concentration
- s is the binding site size.
- Scheme 19 summarizes the DNA affinity constants for the compounds.
- the affinity constants are high (10 5 to 10 6 M ⁇ 1 ) and the data clearly show, in unison with Scheme 18, that both the non-macrocyclic and macrocyclic Au(III) complexes are DNA intercalators. Consequently, the compounds are capable of disrupting the topoisomerase I or II DNA religation step and/or its ability to bind DNA (competitive inhibition). In short, the compounds of this invention act as poisons and/or inhibitors of the human topoisomerase I and/or II enzyme in vitro.
- the Hep-G2 cytotoxicity assay confirmed the expected good cytotoxicity displayed in the NCI-60 screen of the compound.
- the Caco-2 transport data clearly demonstrate that the test agent is not an efflux transporter substrate and has the ability to freely pass across a monolayer of Caco-2 cells (a model for the human small intestine wall or mucosa) without much preference for direction.
- the Caco-2 data are especially important as many drugs fail due to poor membrane transport/absorption.
- the transport rates for MA_AuPr are summarized in Scheme 21.
- ADME-Tox result shown in Scheme 20 The only possibly concerning ADME-Tox result shown in Scheme 20 is that the test compound did not bind to plasma protein and was, in fact, not identified in a structurally intact form by LC-MS in the protein-free fraction (i.e. the molecular ion peak for MA_AuPr was not detected in the mass spectrum).
- the t 1/2 of MA_AuPr in plasma was ⁇ 20 min. This suggests fast conversion of the compound to another species in the presence of plasma constituents and could suggest covalent interaction with proteins or metal ion aquation/hydrolysis possibly by enzyme action.
- the Applicant is of the firm opinion that encapsulation of the non-macrocyclic Au(III) compounds belonging to Formula (I) in ⁇ -cyclodextrin or other water-soluble encapsulating agents such as curcubit-[8]-uril will permit increased plasma half-lives for these compounds.
- Encapsulation for metallo-drug transport and stabilization is well-established in the literature, 34 and has been shown to enhance the redox and plasma stability of cisplatin analogues. 34 It should be noted that enhanced plasma stability for the macrocyclic Au(III) complexes belonging to Formula (I) is anticipated because hydrolysis of the Au—N pyrrole bonds in the macrocycle is quite unlikely. Experiments investigating this concept further are currently underway in our laboratory.
- N/D Not determined due to lowest concentration tested is the returned MEC.
- AC 50 The concentration at which 50% maximum effect is observed for each cell health parameter.
- N/A The response was not significantly above control to determine an AC 50 value.
- First Signal (x) The cell health feature which responds at the lowest observed dose.
- the data for MA_AuPr in Scheme 22 are consistent with a cytotoxic compound capable of inducing apoptosis (programmed cell death) and, indeed, a compound that performs better than the control drug.
- the lowest MEC response data indicate that the compound MA_AuPr has resulted in an increase in membrane permeability (indicating general cell death), an increase in mitochondrial mass (indicating an adaptive response to cellular energy demands), and an increase in mitochondrial potential (implying adaption to cellular energy requirements).
- cell health parameters which respond are a loss of total cells per well (indicating toxicity due to necrosis, apoptosis or a reduction in cellular proliferation), an increase in nuclear area (indicating necrosis or G2 cell cycle arrest), an increase in cytochrome c release (implying activation of a signalling cascade leading to apoptosis).
- the latter is particularly relevant as we may rule out cell death by necrosis in the case of MA_AuPr.
- the mechanism of action of the compound thus leads to cell cycle arrest in the G2 phase and the induction of apoptosis (highly desirable for an anticancer drug).
- the lowest AC 50 response indicates that the compound MA_AuPr has resulted in a loss of total cells per well (indicating toxicity due to necrosis, apoptosis or a reduction in cellular proliferation). Since the compound induces cytochrome c release, cytotoxicity involves apoptosis.
- the plasma stability and cytotoxicity of a test drug may be examined more extensively in an animal model (in vivo).
- Scheme 23 shows a graph of 3 LL tumor growth (measured by caliper methods at the University of France) in black mice over a 20-day period at the indicated doses.
- the 3LL cell line is a solid Lewis lung carcinoma cell line of the mouse.
- the compound MA_AuPr despite its modest plasma stability in vitro (Scheme 20) and poor performance against human lung carcinoma cell lines in the NCI-60 screen (Scheme 6a), clearly slows down the growth rate of 3 LL tumors in black mice by about 33% relative to the control after 20 days.
- MA_AuPr In comparison to cisplatin, which reduces the growth rate of 3LL tumors by 76% in 20 days and is a highly effective drug against lung carcinoma cell lines, MA_AuPr has about 43% of the in vivo performance of cisplatin for this particular cancer cell line.
- the gold(III) chelates of this invention out-perform cisplatin for several colorectal carcinoma cell lines, renal carcinomas, and breast cancer cell lines (Scheme 10), so that the data presented in Scheme 23 may be taken as a lower limit of the compound's in vivo cytotoxicity.
- Scheme 24 shows a set of survival data for five groups of four mice receiving from 1 to 30 ⁇ mol/kg doses of MA_AuPr.
- a single dose of the compound was administered by injection over the first week followed by two injections per week per mouse for a total period of 50 days. All of the mice remained healthy and showed no abnormal weight changes over the timeframe of the experiment (mouse mass data not shown, but available as a time dependent plot).
- the results demonstrate that MA_AuPr has an acute toxicity >30 ⁇ mol/kg/week and a chronic toxicity >60 ⁇ mol/kg/week. This is fully consistent with the ADME-Tox data (Scheme 20) which showed that the compound is highly metabolized by liver microsomes.
- ADME-Tox and in vivo toxicology data for MA_AuPr are complementary and collectively indicate that:
- MA_AuPr is a cytotoxic metal complex (a topoisomerase II poison and inhibitor) with a mean in vitro IC 50 value in the low ⁇ M range.
- the general synthetic procedure for the synthesis of all non-macrocyclic ligands in this invention involves the condensation of two equivalents of 1H-pyrrole-2-carbaldehyde or 5-methyl-1H-imidazole-4-carbaldehyde with an appropriate 1,2- or 1,3-diaminoalkane linker unit, which forms a diiminoalkane bridge in the Schiff base condensation product.
- the bis(imine) compounds produced from such condensation reactions are then purified and reacted with a gold(III) salt in a suitable solvent system to form a relatively planar chelate of gold(III).
- This intermediate is not isolated but condensed in situ with a 1,3- or 1,4-diaminoalkane linker unit, which, through the formation of a pair Au-bound imine groups and concomitant loss of two molar equivalents of water, cyclizes the ligand to form the product Au(III) macrocycle as a monocationic complex.
- 1,3-diamines such as 2-ethoxy-1,3-diaminopropane and 2-chloro-1,3-diaminopropane were synthesized by t-boc protection of the two amino groups of 1,3-diamino-2-hydroxypropane followed by reaction of the hydroxy group and subsequent deprotection of the amino groups.
- N,N′-di-t-boc-2-hydroxy-1,3-diaminopropane 1.0 g, 3.5 mmol
- triphenylphosphine 1.5 g, 5.72 mmol
- chloroform 15 mL
- carbon tetrachloride 35 mL
- This solution was refluxed for 5 hours, before the solvents were removed under reduced pressure by rotary evaporation.
- the resulting oil was dissolved in diethylether to precipitate the OPPh 3 and the resulting solution centrifuged to remove the insoluble OPPh 3 .
- the crystalline product can be shown to be clean by thin layer chromatography or 1 H NMR spectroscopy. Single crystals suitable for X-ray crystallography may also be obtained from the re-crystallisation process.
- the procedure and full characterization for N,N′-bis[(1E)-1H-pyrrol-2-ylmethylene]propane-1,3-diamine have, for example, been reported elsewhere. 14
- Typical isolated yields were of the order of 60-70%.
- the product ligands were analysed by 1 H NMR, 13 C NMR, UV/visible and IR spectroscopy. In some cases, crystals suitable for a structure determination by X-ray diffraction were obtained during the re-crystallisation step. Synthetic methods and characterization data for several novel ligands prepared in this way are described below.
- the powder was re-crystallised from 1:30:50 ethanol:THF:hexane (0.290 g, 62% yield).
- the novel ligand was further characterized by 1 H NMR, 13 C NMR, UV/visible and IR spectroscopy.
- UV/vis (ethanol) [ ⁇ max , nm; ⁇ , mol ⁇ 1 dm 3 cm ⁇ 1 ]: 292; 3.81 ⁇ 10 4 .
- This crude material was re-crystallized by slow liquid diffusion of a methanol solution of the complex into diethylether.
- the re-crystallized product may be isolated in 60-70% yield and analysed by X-ray crystallography as well as LCMS, NMR, IR and UV/visible spectroscopy.
- the precipitate was now air stable and was collected by centrifugation.
- This crude material was re-crystallized by slow liquid diffusion of a methanol solution into diethylether.
- the re-crystallized product (52.8 mg, 0.148 mmol, 67% yield) was shown to be MA_AuPr by X-ray crystallography as well as NMR, IR and UV/visible spectroscopy.
- the salt [Bu 4 N][AuCl 4 ] was found to be more satisfactory than the more conventional [Na][AuCl 4 ] as the source of gold(III) ions for two reasons.
- Second, the salt [Bu 4 N][AuCl 4 ] is soluble in non-polar solvents, unlike [Na][AuCl 4 ] which is only soluble in polar solvents. This therefore means that the chelation reaction can be carried out in non-polar solvents.
- the free ligand was synthesized following the literature method. 41 A solution of tert-butylammonium tetrachloroaurate(III) (80 mg, 0.138 mmols) and tert-butylammonium hexafluorophosphate(V) (160 mg, 0.414 mmols) in dichloromethane (15 mL) was added dropwise to the free ligand, 12,13-dihydro-14H-6,9:17,20-diepimino[1,6]diazacyclo-heptadecino [12,13-b]quinoxaline (99 mg, 0.275 mmols) in dichloromethane (20 mL). The solution was refluxed for 16 hours.
- 2,3-Bis(5′-formylpyrrol-2′-yl)quinoxaline alternatively named 5,5′-quinoxaline-2,3-diylbis(1H-pyrrole-2-carbaldehyde)
- 5,5′-quinoxaline-2,3-diylbis(1H-pyrrole-2-carbaldehyde) was synthesized by the literature method 41
- a solution of 2,3-bis(5′-formylpyrrol-2′-yl)quinoxaline (54 mg, 0.172 mmols) in dichloromethane (10 mL) was added dropwise to tert-butylammonium tetrachloroaurate(III) (100 mg, 0.172 mmols) in dichloromethane (20 mL).
- This complex was prepared by the same method used for the synthesis of 1.1Y 1 b but with 1,4-diaminobutane (15.2 mg, 0.172 mmols) as the macrocycle-closing diamine to give a brown powder of compound 1.5Y 1 a, ⁇ 12,13,14,15-tetrahydro-6,9:18,21-diepimino[1,6]diazacycloctadecino[12,13-b]quinoxalinato ⁇ gold(III) hexafluorophosphate(V) (20 mg, 16%).
- Table 2 shows a summary of X-Ray data of some of the gold(III) chelates of the invention.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- THIS INVENTION relates to novel chemotherapeutic agents. It relates in particular to novel bis(pyrrolide-imine) and bis(imidazolato-imine) gold(III) Schiff base complexes as chemotherapeutic agents.
- The use of metal complexes in medicine can be traced back to 3500 BC and due to its particular physical and chemical properties gold has always been one of the many metals in use1,2 Despite its wide use most of the gold based drugs have not been designed specifically for their function, and their mode of action is often unknown2 The use of gold(0) is limited and is mostly used as a non-irritating food decoration and additive1 Most of the gold-based drugs employ gold(I) and gold(III).1
- The use of gold(I) based drugs has until recently been the main focus of medicinal research.3,4 Their usefulness has mostly been in the treatment of rheumatoid arthritis, but testing against different cancer cell lines has been reported.3 Gold(I) is a soft d10 metal ion. The most common coordination geometry for gold(I) complexes is linear, with the molecules usually consisting of a central gold(I) ion coordinated by either phosphorous or sulfur donor ligands.4,5 Au(I) complexes undergo facile ligand exchange in aqueous solutions, with the rate of ligand exchange increasing in the order R3P<RS−<X−. The lability of the ligands contributes to both the therapeutic activity of Au(I) antiarthritic compounds and the side effects observed with these drugs.4 One of the most well known of the gold(I) drugs is Auranofin (Scheme 1) which is widely used in the treatment of rheumatoid arthritis.
- Auranofin and its many derivatives have also become the focus of research into gold(I) based anti-cancer agents. Several complexes have been found to exhibit cytotoxicity greater than that of cisplatin against melanoma and leukemia cancer cell lines in particular.5 The in vitro test results of many gold(I) chelates against various human cancer cell lines have been promising.4,5
- However, many of these complexes have never entered into clinical trials, since they have been associated with cardiotoxicity in preclinical trials.2 Due to this cardiotoxicity of gold(I) chelates, gold(III) has become the focus of research into gold based chemotherapeutic agents.5,6
- One of the first metal based drugs that was used in the treatment of cancer was cisplatin.6,7 Cisplatin is still widely used today in the treatment of several types of tumors, particularly testicular cancer. Its use is, however, hindered by some clinical problems such as a severe toxicity towards non-cancerous tissue and the frequent occurrence of initial and acquired resistance to the treatment.6 The most concerning adverse side effect is nephrotoxicity correlated to platinum binding and inactivation of renal thiol-containing enzymes.6 These drawbacks to the success of cisplatin in anticancer chemotherapy has raised great interest in the study of metal complexes to be used as antitumor agents, instigating the ongoing investigation of alternative metal-based drugs. The allure of gold(III) as an anti-tumor agent is that it has a d8 electron configuration, with vacant d(x2-y2) orbitals, and therefore adopts a rigorously square planar coordination geometry. Gold(III) is therefore isostructural and isoelectronic to platinum(II).8 Despite the similarity to platinum(II) literature relating to the use of gold(III) as a chemotherapeutic agent is scarce.6 The rarity of data on gold(III) complexes probably derives from their high redox potential and relatively poor stability, which make their use rather problematic under physiological conditions.5,6 The gold(III) ion can be readily reduced to the more stable gold(I) ion or even metallic gold(0) under the in vivo reducing conditions, characteristic of the mammalian environment.5 The coordination of a ligand, which is a strong σ-donor and π-acceptor ligand that can stabilize the gold(III) ion under physiological conditions is therefore critical if gold(III) is to be used in the treatment of cancer.5,9
- There are currently no commercially available gold(III) compounds being used as chemotherapeutic agents. There are, however, many gold(III) complexes that have shown very promising in vitro and in vivo activity against many different human cancer cell lines.10 The structures of a range of gold(III) chelates, which have Au—N bonds, that have been tested for cytotoxicity are shown in
Scheme 2. - The two pyridyl gold(III) species, [AuCl3(Hpm)] and [AuCl2(pm)] (Scheme 2) have good cytotoxicity towards a range of human cancer cell lines, particularly human ovarian cancer cell lines. The results of these tests although promising were comparable to the screening results of NaAuCl4 which is their parent compound.10 The other drawback of these compounds is that although stable in organic solutions, they are susceptible to reduction in aqueous buffer media, which limits their practical usefulness.10,11 The bipyridine type complexes, [Au(bipy)(OH)2][PF6] and [Au(bipy-H)(OH)][PF6] were, on the other hand, found to be stable in aqueous buffer media. Unfortunately they were found to interact with calf thymus DNA only weakly. Despite this weak interaction with calf thymus DNA, both bipyridyl gold(III) complexes show IC50 values falling into the micromolar range against an ovarian carcinoma cell line. [Au(bipy-H)(OH)][PF6] is the most active of the two compounds. The results of the tests against other ovarian cancer cell lines as well as leukemia cell lines were less encouraging.9
- The gold(III) complexes with multidentate N-donor ligands; [Au(phen)Cl2]Cl, [Au(terpy)Cl]Cl2, [AuCl(dien)]Cl2, [Au(cyclam)](ClO4)2Cl and [Au(en)2]Cl2, showed reasonable stability in physiological buffer solutions at 37° C. These gold(III) complexes have been greatly stabilized by the chelation of the gold(III) ion to polyamine ligands. This stabilization was evidenced by measurements of the reduction potentials of the complexes.8,10 The stabilization was less evident for the less basic phenanthrene and terpyridine ligands.8 With the exception of the complex [Au(cyclam)](ClO4)2Cl, all complexes exhibited good cytotoxicity against the human ovarian cancer cell line A2780. These complexes also exhibited good cytotoxicity towards the cisplatin-resistant A2780 ovarian cancer cell line; this suggests that gold(III) compounds might overcome the phenomenon of drug resistance.8,10 The free ligands that were coordinated to a gold(III) ion to give the complexes were also screened against the same cancer cell lines to ensure that the cytotoxicity was a result of the presence of the gold(III) ion. These test results showed that the free ethylenediamine ligand was devoid of any activity. The potency of free phenanthrene and terpyridine, on the other hand, was comparable to that of the respective gold(III)complexes making the screening results of these chelates difficult to interpret. The study did, however, prove that the cytotoxicity of [Au(en)2]Cl2 was a direct consequence of the presence of the gold(III) ion.10
- The complex [Au(azpy)Cl2]Cl, which contains a bidentate N-donor ligand, exhibited promising cytotoxic activity in cisplatin-sensitive and cisplatin-resistant ovarian carcinoma and leukemia cancer cell lines. Interestingly, solutions of [Au(azpy)Cl2]Cl underwent a cyclization reaction under physiological conditions leading to the formation of a tricyclic cationic organic compound, which also exhibited good cytotoxic activity.10,12
- The gold(III) dithiocarbamate complexes, are examples of gold(III) chelates with Au—S bond which are bound to ligands through a sulfur atom. Examples of dithiocarbamate complexes that have been screened against various cancer cell lines are shown below in
Scheme 3. - The Gold(III) dithiocarbamate complexes that have been screened against various human cancer cell lines exhibited greater cytotoxic effects compared to cisplatin. The complexes were also bioactive against drug resistant cancer cell lines and induced apoptosis.6,7 The compounds have proven to be stabile under physiological conditions and readily bind to calf thymus DNA, inhibiting both DNA and RNA synthesis. Experiments on red blood cells indicated that haemolytic properties might contribute significantly to the bioactivity of the agents. The complexes triggered cancer cell death via apoptotic and non-apoptotic pathways and affected mitochondrial functions.6,7,10 The free ligand ESDT (Scheme 3) did not exhibit proteosome inhibitory activity and the parent gold salts KAuCl4 and KAuBr4 also showed weaker inhibitory activities than (ESDT)AuBr2.
- Although the in vitro anti-cancer activity of gold(III) compounds has been documented for more than three decades, very few demonstrate promising in vivo anti-cancer activities. Among the gold(III)compounds in the literature that have undergone in vivo testing are the gold(III) dithiocarbamate compounds, which inhibited approximately 50% growth of breast cancer cells a month after the first dose of the compound.13
- The gold(III) chelates of this invention have tetradentate dianion ligands. More specifically they are N2N′2 tetradentate ligands and therefore are closely related to the highly cytotoxic gold(III) tetraarylporphyrins. The advantage of tetradentate ligands is that they are better able to stabilize the gold(III) cation against reduction under physiological conditions and are therefore potentially more useful as drugs.5,9 Coordination of a tetradentate dianionic ligand to gold(III) gives a mono-cationic gold(III) compound having a planar geometry. These mono-cationic complexes have a similar overall structure to lipophilic organic cations, which have proven to be effective chemotherapeutic agents.13 The structures of a selection of known gold(III) chelates with tetradentate, dianionic ligands13 are set out in
Scheme 4. - The gold(III) porphyrins have proven to be stable under physiological conditions. The complexes [Au(dcbpb)]Cl and [Au(salen)]Cl, on the other hand, show signs of slow decomposition under similar conditions.13 [Au(TPP)]Cl has displayed promising anticancer activities toward a panel of human cancer cell lines including nasopharyngeal carcinoma, promyelocytic leukaemia, hepatocellular carcinoma, cervical epithelioid carcinoma, and oral epidermoid carcinoma.13 The IC50 values of [Au(TPP)]Cl ranged between 0.11 and 0.73 μM. These IC50 values show that [Au(TPP)]Cl is several hundred times more cytotoxic than cisplatin. This compound also shows significant cytotoxicity against KB-3-1 and its multi-drug resistant (KB-V1) variant. The latter possesses a high level of membrane P-glycoproteins, which exclude drugs such as vinblastine and doxorubicin.13 To investigate the cytotoxic effect of [Au(TPP)]Cl on non-cancerous cells, the cytotoxicity toward peripheral blood mononuclear cells (PBMCs) from healthy individuals and CCD-19Lu cells, which is a fibroblast cell line derived from normal lung tissue, were examined. Results by MTT assay revealed that [Au(TPP)]Cl exhibits at least ten-fold higher cytotoxicity to cancer cells than non-cancerous cells.13 The presence of gold(III) ions has been proven to be critical for the observed in vitro chemotherapeutic properties. This conclusion is based on the inactivity of [ZnII(TPP)]. The zinc(II) analogue of [Au(TPP)]Cl exhibits an IC50 value greater than 50 μM. The gold(III) ion is unstable under physiological conditions as it undergoes reduction to colloidal gold. The porphyrin ligand is, however able to stabilize the gold(III) ion and it is hypothesized that [Au(TPP)]+ acts as a stable lipophilic planar cation for binding to bio-molecular target(s) through non-covalent interactions.13
- The cytotoxic properties of the gold(III) salen Schiff base complexes and the bis(pyridyl)carboxamide gold(III) complexes have also been evaluated.13 These compounds have been shown to exhibit a cytotoxicity comparable to that of cisplatin with a IC50 values in the range of 10-30 μM.
- There are two different pathways via which a compound can cause cell death, these are apoptosis and necrosis. Apoptosis is characterized by an ordered series of biochemical and biophysical reactions that are regulated by various genes, this is in contrast to necrosis which is premature cell death. While apoptosis often provides beneficial effects to the organism, necrosis is almost always detrimental, and can be fatal. Apoptosis does not trigger inflammatory tissue reactions, and thus is advantageous for cytotoxic chemotherapeutic agents to be able to induce apoptotic cell death as opposed to necrosis. The compound [Au(TPP)]Cl induced cytotoxicity in NPC cells via an apoptotic pathway.13 By means of confocal imaging, typical apoptotic morphological changes were detected, including the formation of apoptotic bodies, chromatin condensation and DNA fragmentation. The induced apoptosis was also confirmed by the oligonucleosomic degradation of cellular DNA, as this type of chromatin degradation is characteristic of apoptosis. These experiments confirm that [Au(TPP)]Cl induces apoptotic cell death in NPC cells as opposed to necrosis.13 The dithiocarbamate gold(III) complexes were also found to cause apoptosis as opposed to necrosis6,7 this would suggest that gold(III) chelates could potentially favour an apoptotic pathway as opposed to a necrotic pathway. This would make them more attractive chemotherapeutic agents.
- Tetradentate Schiff base ligands comprising two pyrrole groups bridged by a synthetically variable di(azomethine) unit have been known for several decades.14 However, studies of both the free base ligands as well as their metal chelates are quite limited.14 Coordination of this class of ligands to a metal cation usually occurs with the concomitant deprotonation of the pyrrole NH groups, this means that they are N2N′2 tetradentate, dianionic ligands. The ligands have been previously bound to Ru(II), Pd(II), Ni(II), Co(III), Mn(II), Sm(II), Pt(II) and Fe(III).15-23 Chelation of the former by the dianionic ligand will result in a neutral metal chelate, with the exception of Co(III) and Fe(III), which will give a monocationic complex. These metal chelates have been used as hydrogenation catalysts when coordinated to Pd(II)16 as well as high efficiency red electrophosphorescence materials when chelated to Pt(II).22 The complexes also show a similar coordination geometry, regardless of the electronic configuration of the metal ion. The metal ions exhibiting a nominally square planar coordination geometry, regardless of whether the bis(imine) linkage is aromatic or a straight or substituted alkyl group. The bridging does, however, affect the extent to which the metal ion is distorted from the optimum square planar geometry. Short bridges, of two carbons in length, whether aromatic or alkyl result in a smaller bite angle of the ligand. This small bite angle manifests itself as an acute Nimine-M-Nimine bond angle.16,23 The longer three carbon bridge allows for a larger bite angle and the Nimine-M-Nimine bond angle therefore tends towards a right angle.16
- The free base bis(pyrrole-imine) compounds have been shown to exhibit fascinating supramolecular structures both with aromatic24 and alkyl14 bridges. The pyrrole N—H and imine type nitrogen atoms form a highly predictable hydrogen bonding motif. The compounds with aromatic bridges have even been used to form distinct nanostructures, with the effect of isomeric molecules being examined in an attempt to try and further understand the self assembly of organic molecules into distinct nanostructures.24
- The present invention provides new classes of gold(III) bis(pyrrolide-imine) and bis(imidazolato-imine) compounds. Several of these compounds have been shown to be cytotoxic towards a wide range of human cancer cell lines having an activity similar to, or better than, cisplatin which is currently the industry standard. The most active compound has been proven in vitro to be a poison of topoisomerase II at low concentrations (EC50=0.5 μM) and a catalytic inhibitor of the enzyme at higher concentrations (50 μM).
- An extensive search of the literature as well as the Cambridge Structural Database (CSD) has confirmed that the gold(III) chelates of the invention are new. Neither the structures nor the syntheses of the bis(pyrrolide-imine) and bis(imidazolato-imine) gold(III) Schiff base complexes of the invention have been reported and, accordingly, there has been no report of the use of the gold(III) chelates of the invention as cytotoxic agents for the treatment of cancer.
- According to a first aspect of the invention, there is provided a compound selected from compounds of the Formula (I),
- in which
- W is independently selected from W1, W2, W3, W4, W5,
- or W represents a pair of substituents independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl or C1-C6 amide in which the amide is optionally part of a linking chain, and the Zn—Zn′ bonds (n=4-17; n′=n+1) are optionally of any whole or partial bond order,
- Y is Y1
- or Y represents a pair of substituents independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl,
- or Y is optionally a bridging structure that may comprise one or more C1-C6 amide, C1-C6 ether, or C1-C6 ester groups,
- R-R39 are independently selected from no substituent, a lone pair of electrons, H, halogen, C5-C6 aryl, C1-C12 alkyl, amine, C1-C6 alkylamine, C1-C6 amide, nitro, cyano, carboxyl, C1-C6 ester, phosphane, thiol, C1-C6 thioether, OR40 , and suitable pairs of adjacent R groups (R-R39) may optionally together form part of a C5 or C6 aryl ring, a Z5 or Z6 ring,
- R40 is independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl, C1-C6 ester, poly(—C2O—), amine, and C1-C6 alkylamine,
- Z-Z24 are independently selected from C, N, P, O, and S, and
- X− is a pharmaceutically acceptable anion.
- The anion X− may be selected from halide, hexafluorophosphate, nitrate, and triflate.
- Examples of representative structurally characterized and tested compounds of the invention are the following compounds.
- Compound 1.1a (MA_AuPr) in which chelate substituents R-R5 are H, Z-Z3 are C, the bridge W is —CH2CH2CH2—, Y is 2H, and the anion X is Cl−.
- Compound 1.1b (MA_AuDM) in which chelate substituents R-R5 are H, Z-Z3 are C, the bridge W is —CH2C(CH3)2CH2—, Y is 2H, and the anion X is Cl−.
- Compound 1.1c (MA_AuOH) in which chelate substituents R-R5 are H, Z-Z3 are C, the bridge W is —CH2CH(OH)CH2—, Y is 2H, and the anion X is Cl−.
- Compound 1.1Y1a (KA_AumacroPr) in which chelate substituents R-R5 are H, Z-Z3 are C, the bridge W is —CH2CH2CH2—, Y is Y1, where R46-R49 are H, Z29 and Z34 are N, Z30-Z33 are C, and the anion X is PF6 −.
- Compound 1.1Y1b (KA_AumacroDM) in which chelate substituents R-R5 are H, Z-Z3 are C, the bridge W is —CH 2C(CH3)2CH2—, Y is Y1, where R46-R49 are H, Z29 and Z34 are N, Z30- Z33 are C, and the anion X is PFC.
- Compound 1.5Y1a (KA_AumacroBu) in which chelate substituents R-R5 are H, Z-Z3 are C, the bridge W is —CH2CH2CH2CH2—, Y is Y1, where R46-R49 are H, Z29 and Z34 are N, Z30-Z33 are C, and the anion X is PF6 −.
- Compound 1.1f (KA_AuMeImPr) in which chelate substituents R and R5 are H, R1 and R4 are CH3, R2 and R3 are lone pairs of electrons, Z and Z3 are C, Z1 and Z2 are N, the bridge W is —CH2CH2CH2—, Y is 2H, and the anion X is PF6 −.
- Compound 1.1g (KA_AuMeImDM) in which chelate substituents R and R5 are H, R1 and R4 are CH3, R2 and R3 are lone pairs of electrons, Z and Z3 are C, Z1 and Z2 are N, the bridge W is —CH2C(CH3)CH2—, Y is 2H, and the anion X is PF6 −
-
Schemes - The single crystal X-ray structural data for compounds 1.1a, 1.1f, and 1.1Y1a are summarized in Table 1. Other crystallographically characterized complexes of the invention are summarized in Table 2.
-
TABLE 1 Crystal data and structure refinement details for MA_AuPr (1.1a), KA_AumacroPr (1.1Y1a), and KA_AuMelmPr (1.1f). Compound MA_AuPr KA_AumacroPr KA_AuMeImPr Formula C13H14AuCIN4 C21H16AuN6F6P C13H16AuF6N6P Cell setting Triclinic Monoclinic Monoclinic Space group P-1 P2/c Cc Formula weight 458.70 694.33 598.25 a/Å, b/Å, c/Å 7.5888(4), 16.473(5), 16.348(5), 9.4183(3), 6.980(5), 12.015(5), 10.5118(4) 18.804(5) 9.488(5) α/°, β/°, γ/° 68.707(4), 90, 105.675(5), 90, 106.865(5), 72.787(4), 90 90 72.194(4) T/K 140(2) 173(2) 295(2) Z 2 4 4 V/Å3 651.86(5) 2081.7(17) 1783.5(13) Density (g cm−3) 2.337 2.2155 2.228 μ, (mm−1) 11.479 7.220 8.410 Crystal 0.10 × 0.10 × 0.50 × 0.02 × 0.45 × 0.25 × Dimensions (mm3) 0.10 0.01 0.15 Radiation λ (Å) 0.71073 0.71073 0.71073 Total Data 10737 14581 6002 Collected Unique Data 4510 [R(int)] = 4010 [R(int)] = 2635 [R(int)] = 0.0173 0.060 0.032 Refinement Full-matrix least- Full-matrix least- Full-matrix least- Method squares on F2 squares on F2 squares on F2 Goodness-of-fit on 1.032 0.940 1.020 F2 Final R indices R1 = 0.0165 R1 = 0.0320 R1 = 0.0271 [I>2sigma(I)] wR 2 = 0.0403 wR2 = 0.0703 wR2 = 0.0660 Final R indices R1 = 0.0189 R1 = 0.0452 R1 = 0.0288 [all data] wR2 = 0.0406 wR2 = 0.0733 wR2 = 0.0655 Largest diff. 1.697/−1.902 2.282/−1.453 0.134/−1.296 peak/hole - It is noteworthy that other anions may be used to crystallize the cations of this invention. For example, we have recently acquired X-ray data for the triflate salt of KA_aumacroDM (C24H20AuF3N6O3S, monoclinic space group Cc, a=17.092(5) Å, b=25.520(5) Å, c=13.625(5) Å, α=90°, β=119.057(5)°, γ=90°, V=5195(3) Å3, Z=8, T=−153(2)° C.).
- The Applicant has found that MA_AuPr (1.1a), by way of example, has several advantages over currently available inorganic chemotherapeutic agents in clinical use. Firstly, the synthesis of the ligands belonging to the 1.1a-1.1f series of compounds is a simple one-pot reaction, requiring minimal purification. Chelation of the ligand to gold(III) is simple and gives a clean easily re-crystallized product. Derivatization of the parent ligand was found to be possible and different derivatives showed varying activity, suggesting that there is a structure/activity relationship between the different derivatives. In vitro testing showed that the chelate 1.1a was more effective than cisplatin against ca. 25% of the 60 human cancer cell lines against which it was tested. The in vitro mechanism of action of the drug has been established and is highly specific. This indicates that the activity of the drug can be carefully controlled.
- According to a second aspect of the invention, there is provided a compound selected from compounds of the Formula (I),
- in which
- W is independently selected from W1, W2, W3, W4, W5,
- or W represents a pair of substituents independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl or C1-C6 amide in which the amide is optionally part of a linking chain, and the Zn-
Z n 40 bonds (n=4-17; n′=n+1) are optionally of any whole or partial bond order, - Y is Y1
- or Y represents a pair of substituents independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl,
- or Y is optionally a bridging structure that may comprise one or more C1-C6 amide, C1-C6 ether, or C1-C6 ester groups,
- R-R39 are independently selected from no substituent, a lone pair of electrons, H, halogen, C5-C6 aryl, C1-C12 alkyl, amine, C1-C6 alkylamine, C1-C6 amide, nitro, cyano, carboxyl, C1-C6 ester, phosphane, thiol, C1-C6 thioether, OR40 , and suitable pairs of adjacent R groups (R-R39) may optionally together form part of a C5 or C6 aryl ring, a Z5 or Z6 ring,
- R40 is independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl, C1-C6 ester, poly(—C2O—), amine, and C1-C6 alkylamine,
- Z-Z24 are independently selected from C, N, P, O, and S, and
- X− is a pharmaceutically acceptable anion for the treatment of cancer.
- The anion X− may be selected from halide, hexafluorophosphate, nitrate, and triflate.
- According to a third aspect of the invention, there is provided a pharmaceutical composition, the composition including at least one compound selected from compounds of the Formula (I),
- in which
- W is independently selected from W1, W2, W3, W4, W5,
- or W represents a pair of substituents independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl or C1-C6 amide in which the amide is optionally part of a linking chain, and the Zn-Zn′ bonds (n=4-17; n′=n+1) are optionally of any whole or partial bond order,
- Y is Y1
- or Y represents a pair of substituents independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl,
- or Y is optionally a bridging structure that may comprise one or more C1-C6 amide, C1-C6 ether, or C1-C6 ester groups,
- R-R39 are independently selected from no substituent, a lone pair of electrons, H, halogen, C5-C6 aryl, C1-C12 alkyl, amine, C1-C6 alkylamine, C1-C6 amide, nitro, cyano, carboxyl, C1-C6 ester, phosphane, thiol, C1-C6 thioether, OR40, and suitable pairs of adjacent R groups (R-R39) may optionally together form part of a C5 or C6 aryl ring, a Z5 or Z6 ring,
- R40 is independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl, C1 -C6 ester, poly(—C2O—), amine, and C1-C6 alkylamine,
- Z-Z24 are independently selected from C, N, P, O, and S, and
- X− is a pharmaceutically acceptable anion.
- The anion X− may be selected from halide, hexafluorophosphate, nitrate, and triflate.
- The pharmaceutical composition may be for use in the treatment of cancer.
- According to a fourth aspect of the invention, there is provided a method of treating cancer, the method including the step of administering, to a subject in need of treatment, a pharmaceutically effective amount of at least one compound selected from compounds of Formula (I),
- in which
- W is independently selected from W1, W2, W3, W4, W5,
- or W represents a pair of substituents independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl or C1-C6 amide in which the amide is optionally part of a linking chain, and the Zn- Zn′ bonds (n=4-17; n′=n+1) are optionally of any whole or partial bond order,
- Y is Y1
- or Y represents a pair of substituents independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl,
- or Y is optionally a bridging structure that may comprise one or more C1-C6 amide, C1-C6 ether, or C1-C6 ester groups,
- R-R39 are independently selected from no substituent, a lone pair of electrons, H, halogen, C5-C6 aryl, C1-C12 alkyl, amine, C1-C6 alkylamine, C1-C6 amide, nitro, cyano, carboxyl, C1-C6 ester, phosphane, thiol, C1-C6 thioether, OR40 , and suitable pairs of adjacent R groups (R-R39) may optionally together form part of a C5 or C6 aryl ring, a Z5 or Z6 ring,
- R40 is independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl, C1-C6 ester, poly(—C2O—), amine, and C1-C6 alkylamine,
- Z-Z24 are independently selected from C, N, P, O, and S, and
- X− is a pharmaceutically acceptable anion.
- The anion X− may be selected from halide, hexafluorophosphate, nitrate, and triflate.
- According to a fifth aspect of the invention, there is provided the use of a compound selected from compounds of Formula (I) has hereinbefore described in the manufacture of a medicament for the treatment of cancer.
- The invention described thus provides a new class of gold(III) bis(pyrrolide-imine) and bis(imidazolato-imine) Schiff base complexes for use as novel anticancer chemotherapeutic agents. These complexes consist of a central gold(III) ion chelated by a N2N′2 tetradentate bis(N-heterocycle-imine) type ligand. Upon coordination of the gold(III) ion, the two pyrrole-type nitrogen atoms (N—H groups) are deprotonated, giving the ligand an overall charge of −2. The metal ion complex therefore has an overall charge of +1; hence the chelates are associated with an anion. The complexes were designed to be predominantly planar which allows the gold(III) chelates to intercalate between DNA base pairs. The overall charge on the cation allows for favorable electrostatic interactions with the negatively charged phosphate backbone of the DNA double helix. The molecular target for the gold(III) complexes is thus DNA (and possibly also related nucleotides). Once the drug has intercalated genomic DNA in cells, it prevents DNA transcription (and thus cell growth), separation of daughter chromatids during mitosis (and thus cell division), and/or maintenance of the DNA duplex by interfering specifically with the normal functioning of either of the essential enzymes topoisomerase I or topoisomerase II. Compound 1.1a, for example, acts as a topoisomerase II poison at low concentrations and an inhibitor of the enzyme at high concentrations (topoisomerase II is critical for cell replication, being responsible for the decatenation of daughter chromatids during mitosis). Compound 1.1Y1a (KA_AumacroPr), on the other hand, acts as a catalytic inhibitor of both topoisomerase I and topoisomerase II.
- The gold(III) chelates of the invention are novel in design and structure and their mode of synthesis is novel. The complexes are readily crystallized, easily purified, and have been fully characterized. The complexes exhibit a highly specific mode of action (all of the compounds target topoisomerase II and some also target topoisomerase I). The most active compound shows good activity (mean GI50=7 μM; mean IC50=20 μM) against multiple cancer cell lines over the full NCI-60 screen. The mechanism of action has been proven to be dependent on the presence of the gold(III) ion since the metal-free complexes are inactive.
- In preferred embodiments of the invention, Y may represent two hydrogen atoms or Y1. For example, Y may be Y1, and Z19 and Z24 may be N. In another preferred embodiment Z20-Z23 may be C.
- The groups R-R5 may be selected from H, C1-C3 alkyl, O—C1-C3 alkyl, hydroxyl and halogen. In particular the C1-C3 alkyl group may be a methyl group, the O—C1-C3 alkyl group may be an O-ethyl group and the halogen may be chlorine.
- In other preferred embodiments W may be selected from W1, W2, W3 or W4. The groups R6-R27 may then be selected from H, C1-C3 alkyl, O—C1-C3 alkyl and halogen. The C1-C3 alkyl group may be a methyl group, the O—C1-C3 alkyl may be an O-ethyl group and the halogen may be chlorine.
- More preferred compounds are compounds selected from:
- 2,2′-{propane-1,3-diylbis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) chloride,
- 2,2′-{(2,2-dimethylpropane-1,3-diyl)bis[nitrilo(E)methylylidene]} bis(pyrrol-1-ido)gold(III) chloride,
- 2,2′-{(2-hydroxypropane-1,3-diyl)bis[nitrilo(E) methylylidene]}bis(pyrrol-1-ido)gold(III) hexafluorophosphate(V),
- 2,2′-{(2-ethoxypropane-1,3-diyl)bis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) hexafluorophosphate(V),
- 2,2′-{(2-chloropropane-1,3-diyl)bis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) hexafluorophosphate(V),
- 2,2′-{ethane-1,2-diylbis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) hexafluorophosphate(V),
- 2,2′-{(2S)-propane-1,2-diylbis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) hexafluorophosphate(V),
- 2,2′-{(1R,2R)-cyclohexane-1,2-diylbis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) hexafluorophosphate(V),
- 2,2′-{(1S,2S)-cyclohexane-1,2-diylbis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) hexafluorophosphate(V),
- 2,2′-{cyclohexane-1,2-diylbis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) hexafluorophosphate(V)
- 2,2′-{(4-methylbenzene-1,2-diyl)bis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) nitrate(V),
- 4,4′-{propane-1,3-diyl)bis[nitrilo(E)methylylidene]}bis(5-methylimidazol-1-ide)gold(III) hexafluorophosphate(V),
- 4,4′-{(2,2-dimethylpropane-1,3-diyl)bis[nitrilo(E)methylylidene]}bis(5-methylimidazol-1-ide)gold(III) hexaflurophosphate(V),
- {12,13-dihydro-14H-6,9:17,20-diepimino[1,6]diazacyclo-heptadecino[12,13-β]quinoxalinato}gold(III) hexafluorophosphate(V),
- {12,14-dihydro-13,13-dimethyl-6,9:17,20-diepimino[1,6]diazacyclo-heptadecino[12,13-β]quinoxalinato}gold(III) hexafluorophosphate(V),
- {12,13,14,15-tetrahydro-6,9:18,21-diepimino[1,6]diazacycloctadecino[2,13-b]quinoxalinato}gold(III) hexafluorophosphate(V), and
- {13-chloro-12,14-dihydro-6,9:7,20-diepimino[1,6]diazacyclo-heptadecino[12,13-β]quinoxalinato}gold(III) hexafluorophosphate(V).
- The invention extends further to a pharmaceutical composition comprising at least one compound as hereinbefore described.
- The invention extends to a method of preparing a compound of Formula (I), which includes the steps of condensing a diamine of the general formula A
- simultaneously or consecutively with a carbonyl compound selected from compounds of the general formula B, C and D
- to produce a diimine Schiff base of the general formula E or F
- and reacting the diimine of general formula E or F with a tetraalkylammonium tetrahaloaurate(III) to produce the gold(III) compound of the general Formula (I) in which W, Y, R, Z and X are as hereinbefore described.
- The invention extends further to a method of preparing a compound of general Formula (I), which includes the step of reacting a carbonyl compound of the general formula D
- with a tetraalkylammonium tetrahaloaurate(III) and a diamine to produce the compound of general Formula (I) in which W, Y, R, Z and X are as hereinbefore described. The tetraalkylammonium tetrahaloaurate(III) may be tetrabutylammonium tetrachloroaurate(III). The butyl group may be a t-butyl group.
- The method may include reacting the diamine with the tetraalkylammonium tetrahaloaurate (III) in the presence of a salt selected from halides, hexafluorophosphates, nitrates, and triflates to produce the corresponding compound of Formula (I) in which k is the corresponding anion. In particular, the salt may be a tetraalkylammonium hexafluorophosphate such as tetra-t-butylammonium hexafluorophosphate.
- Where the compound of Formula (I) is a chloride the method may include the further step of reacting the compound of Formula (I) in which X− is chloride with a salt selected from halides other than chloride, hexafluorophosphates, nitrates, and triflates to produce a compound of Formula (I) in which X− is the anion of the said salt.
- The invention extends to a method of preparing a 2-substituted 1,3-diamine intermediate of the general formula A1
- or its dihydrochloride salt, in which F is selected from F1 or halogen,
- in which
- R41-R43 are independently selected, H, halogen, Z5 or Z6 aryl, C1-C12 alkyl, C1-C6 alkylamine, C1-C6 amide, carboxyl, C1-C6 ester or OR40,
- R4° is as hereinbefore described, or suitable pairs of adjacent R groups (R41-R43) optionally together form part of a C5 or C6 aryl ring, or
- F is R44, and
- R44 is independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl, C1-C6 ester, poly(-C2O-), amine, C1-C6 alkylamine, and C1-C6 amide or a Z5 or Z6 ring, and
- Z5 and Z6 are as hereinbefore described,
- the method including the steps of converting the hydroxyl group of 2,2,12,12-t-methyl-3,11-dioxo-4,10-dioxa-5,9-diazatridecan-7-ol to the group F.
- The invention extends to bis(pyrrole-imine) ligands selected from:
- 2-ethoxy-N′-bis[(E)-1H-pyrrol-2-ylmethylidene]propane-1,3-diamine, and 2-chloro-N′-bis[(E)-1H-pyrrol-2-ylmethylidene]propane-1,3-diamine.
- The invention extends further to a method for the preparation of tetrabutylammonium tetrachloroaurate, [Bu4N][AuCl4], the method including the step of extracting [Bu4N][AuCl4] from a mixture using an organic solvent-extraction purification step to produce an acid-free, crystalline [Bu4N][AuCl4]. The method may include reacting an aqueous solution of H[AuCl4] and [Bu4N][HSO4] to produce the mixture and extracting the [Bu4N][AuCl4] from the mixture with the organic solvent.
- The invention is now illustrated, by way of example, with reference to the following examples.
-
Scheme 1 Auranofin -
Scheme 5a Partially labeled thermal ellipsoid diagram of the X-ray crystal structure of MA_AuPr. Ellipsoids are rendered as 50% probability surfaces; H atoms are of an arbitrary radius. -
Scheme 5b Partially labeled thermal ellipsoid diagram of the X-ray crystal structure of KA_AumacroPr. Ellipsoids are rendered as 50% probability surfaces; H atoms are of an arbitrary radius. -
Scheme 5c Partially labeled thermal ellipsoid diagram of the X-ray crystal structure of A_AuMeImPr. Ellipsoids are rendered as 30% probability surfaces; H atoms are of an arbitrary radius. -
Scheme 6a Single-dose screening results for MA_AuPr over 60 human cancer cell lines. A negative growth percent is favorable and shows up as a positive bar on the graph. -
Scheme 6b Single-dose screening results for KA_AumacroPr over 60 human cancer cell lines. A negative growth percent is favorable and shows up as a positive bar on the graph. -
Scheme 6c Single-dose screening results for KA_AuMelmPr over 60 human cancer cell lines. A negative growth percent is favorable and shows up as a positive bar on the graph. -
Scheme 8a Dose-response curves for three commercial anticancer drugs (cisplatin, mitomycin, camptothecin) and three Au(III) chelates. The more abrupt the curve, the harder the dose-response function. -
Scheme 8b Dose-response curves (HeLa cells, pH 7.0, 37° C.) for three macrocyclic Au(III) chelates. IC50 values for the complexes against HeLa cells obtained from the least squares data fits (graph) are given in the 3rd column of the table. -
Scheme 9 Plot of −log(GI50/M) for MA_AuPr versus the equivalent data for cisplatin. -
Scheme 10a Comparison of −log(GI50) values for MA_AuPr with commercially available anticancer drugs for selected human cancer cell lines. -
Scheme 10b Comparison of−log(GI50) values for MA_AuPr and MA_AuDM with commercially available anticancer drugs for selected human cancer cell lines. -
Scheme 11 Comparison of the activity profiles of commercial drugs with a known mechanism of action and the two Au(III) chelates MA_AuPr and MA_AuDM. (Group average method, Minkowski distance.) -
Scheme 12 EB gel showing the poisoning at low concentrations (0.5 μM) and catalytic inhibition at higher concentrations (50 μM) of topoisomerase II activity on supercoiled plasmid DNA substrate by MA_AuPr. -
Scheme 13 EB gel showing the inactivity of MA_AuPr against topoisomerase I compared to the chemotherapeutic agent CPT (camptothecin), which is specifically a topoisomerase I poison. -
Scheme 14 EB gel showing the inactivity of MA_H2PrLig (the metal-free ligand) against topoisomerase II compared to the chemotherapeutic agent VP-16 (etoposide), which is specifically a topoisomerase II poison. There is evidence of weak DNA-cleavage induction in the presence of topoisomerase II from the free ligand at 500 μM concentration. -
Scheme 15 EB gel showing the diminished activity of MA_PdPr (the Pd2+ analogue of MA_AuPr) against topoisomerase II compared to the chemotherapeutic agent VP-16 (etoposide), which is specifically a topoisomerase I poison. There is evidence of DNA-cleavage induction in the presence of topoisomerase II at 50 μM concentration (a 100-fold weaker effect than the gold(III) complex). -
Scheme 16 Top: agarose gel electrophoresis topoisomerase II (topo II) DNA cleavage assay (66 ng kinetoplast DNA, 4 U topo II) as a function of the concentration of KA_AumacroPr (complex 1.1Y1a). Lanes 1-4 contain catenated DNA (no topo II), decatenated DNA (topo II present), decatenated DNA (solvent control), and linear DNA, respectively. The lane marked VP-16 contained DNA, topo II, and etoposide (VP-16). Band labels: I, catenated DNA; II, open-circular (OC) DNA; III, linear DNA; IV, closed-covalently circular (CCC) DNA. Lanes 5-13 included compound 1.1Y1a from 5 nM to 500 nM in 10-fold concentration increments, respectively. Bottom: standard dose-response function fit of the experimental titration data (top gel) with (solid line) and without (dashed line) a Hill coefficient. The maximum ESD from triplicate measurements is shown (15%). -
Scheme 17 Inhibition of human topoisomerase/by KA_AumacroPr as determined by supercoiled plasmid DNA relaxation assay (agarose gel electrophoresis). Lanes 2-12 have 5U of topoisomerase I. The enzyme fully relaxes supercoiled (SC) DNA in lanes 3-8 for KA_AumacroPr concentrations ranging from 0-50 nM. At concentrations from 500 nM-500 μM, topoisomerase I exhibits abnormal and incomplete substrate relaxation. -
Scheme 18 Titration of MA_AuPr (1.1a) with calf-thymus DNA inaqueous pH 7 phosphate buffer at 37° C. The data indicate that compound 1.1a is a DNA intercalator. -
Scheme 23 Graph of 3 LL tumor growth in black mice (mean data for 6 subjects) as a function of time and type of anticancer drug. MA_AuPr was administered at a dose of 20 μmol/kg twice weekly and cisplatin at a dose of 26 μmol/kg once weekly. Untreated mice were the control. -
Scheme 24 Mouse survival data as a function of metallodrug dose for MA_AuPr. The graph plots the survival of five groups of four mice on drug concentrations ranging from 1 to 30 μmol/kg for the displayed injection protocols. - In Vitro Anti-Cancer Tests
- The gold(III) complexes of this invention were screened by the National Cancer Institute (NCI, USA) against their panel of 60 different human cancer cell lines. These screens initially entail a one-dose test for the compound at a high concentration (10 μM; e.g.
Schemes 6a-6c). Compounds with a good cytotoxicity profile in the one-dose screen are then subjected to a five-dose screen for the full panel of sixty human cancer cell lines (the so-called 5-dose NCI-60 screen). In the full five-dose screen, the compound concentration is varied in five doses from 10−8 M to 10−4 M in order to establish a dose-response function of percentage cell growth versus the concentration of the test agent. The latter data permits determination of several key parameters indicative of a compound's cytotoxicity, namely, the GI50, IC50, and LC50 values for the test agent (these are the concentrations at which 50% growth inhibition, total growth inhibition, and 50% cell death occur, respectively). These data from 5-dose NCI-60 screens are summarized inScheme 7 for selected chelates of this invention (by way of illustration). Similar data will shortly be available for compounds 1.1Y1b and 1.5Y1a as these derivatives are in 5-dose screens currently at the NCI. - The results of one-dose NCI-60 screens are noteworthy and merit some discussion as they quickly indicate activity profiles, cell-line specificity, and general cytotoxicity for the test agents across multiple human cancer cell lines.
Schemes Scheme 6a), KA_AumacroPr (Scheme 6b), and KA_AuMelmPr (Scheme 6c) obtained by the NCI. These three compounds are the parent derivatives that are representative of the three new types of gold(III) Schiff base chelate relevant to this invention. All other compounds synthesized as part of this invention have been similarly analyzed. - The preliminary cell screening data indicated that the three classes of compounds are inherently more toxic towards some cancer cell lines than others. This suggests that the compounds of the invention are not merely general poisons, but in fact agents with some tumor specificity and specific cellular mechanisms of action. From
Schemes 6a-6c, leukemia, breast, and colon cancer cell lines are inherently more susceptible to the cytotoxic action of MA_AuPr. Breast and leukemia cell lines were, as a group, the most sensitive to KA_AuMelmPr while the macrocyclic derivative KA_AumacroPr showed good cytotoxicity for the majority of the cell lines constituting the groups: (i) non-small lung cancer, (ii) central nervous system cancer, (iii) renal carcinoma, and (iv) breast cancer. - Complexes 1.1a, 1.1 b, and 1.1Y1b were selected by the NCI for a five-dose screen against the full panel of 60 different human cancer cell lines to establish IC50 values and other parameters.
- Complex 1.1c (with a hydroxyl group in the propyl bridge, MA_AuOH) was not sufficiently active in cell cultures to warrant a five-dose screen. The Applicant is of the opinion that cancer cells may have an active defense mechanism against 1.1c, e.g., an efflux pump or derivatization to an inactive form. The hydroxyl group is clearly implicated in the inactivity of the compound because 1.1a which lacks the hydroxyl group is highly active. A summary of the average cytotoxicity data over 60 human cancer cell lines for 1.1a-1.1c and comparison with selected commercial and patented cytotoxic agents is shown in
Scheme 7. Dose-response curves for three commercial anticancer drugs (cisplatin, mitomycin, camptothecin) and three Au(III) chelates are shown inScheme 8a. The more abrupt the curve, the harder the dose-response function.Scheme 8b shows dose-response curves obtained with HeLa cells incubated with the macrocydic gold(III) complexes 1.1Y1a, 1.1Y1b, and 1.5Y1a at 37° C. The data indicate that the complex with the butyl chain as the bridging group W (complex 1.5Y1a) has very good cytotoxicity with a sub-micromolar IC50 value of 370 nM; complexes 1.1Y1a and 1.1Y1b were also cytotoxic and had IC50 values of ca. 3 μM. -
Scheme 7Summary of the average cytotoxicity data over 60 human cancer cell lines for 1.1a-c and comparison with selected commercial and patented cytotoxic agents Drug GI50 (μM) TGI or IC50 (μM) LC50 (μM) MA_AuOH (*) >100 >100 >100 MA_AuDM (*) 12 31 72 MA_AuPr (*) 7(1) 20(3) 49(5) cis-[PtCl2(NH3)2] 2 27 >100 (AuIII(terpy)Cl]Cl2 0.13 11 73 Mitomycin 0.71 6.5 18 Camptothecin 0.04 0.89 33 (*): This work. - The mean cytotoxicity data summarized in
Scheme 7 were compiled over 60 human cancer cell lines from the NCI database. The experimental parameters GI50, IC50, and LC50, are mean concentrations at which 50% growth inhibition, 100% (total) growth inhibition, and 50% cell death occur, respectively. The data show that MA_AuPr is somewhat more cytotoxic than cisplatin and carboplatin when comparing the IC50 and - LC50 values. The dose-response curves for the bis(pyrrolide-imine) chelates of the invention are steeper, or harder, than those of all the compounds compared in
Scheme 7. Of the other drugs shown, only mitomycin (a powerful organic DNA alkylating and cross-linking agent) exhibits a comparably steep mean dose-response function. - The important features to note from the data in
Scheme 7 andSchemes - The three Au(III) macrocycles developed and tested to date (
Scheme 8b) exhibit the best cytotoxicity of all the compounds examined (at least in the HeLa cell line) with softer dose-response profiles more akin to commercial natural product drugs like camptothecin. In particular, the GI50 values for the three compounds 1.1Y1a, 1.1Y1b, and 1.5Y1a are all around 100 nM. Complex 1.5Y1a has a particularly attractive dose-response profile that is better than that of camptothecin (Scheme 8a) because the LC50 value is <10 μM (i.e. about one-third of camptothecin's LC50 value). - Further, the in vitro data suggest that if general and organ-specific toxicity of MA_AuPr is not high in an animal model, i.e., micromolar concentrations of the compound are well-tolerated in vivo, then this new class of Au(III) compounds has a fundamental activity profile unlike any other compounds currently in use or in trials. Most importantly, this new class of compounds might be useful for completely clearing stubborn tumours or cisplatin-resistant tumours (complex 1.5Y1a is clearly an extremely promising candidate for such a role). Small structural changes to the basic ligand structure (compare MA_AuPr with MA_AuDM and MA_AuOH) clearly dramatically alter the mean cytotoxicity profile of the compound. This suggests a strong link between structure and activity and that the synthesis and screening of other derivatives of the basic bis(pyrrolide-imine) chelate system are likely to enhance the cytotoxicity of the lead compound and afford GI50 and IC50 values in the same range as commercially viable drugs such as mitomycin or camptothecin.
-
Scheme 9 shows a plot of −log(GI50/M) for MA_AuPr versus the equivalent data for cisplatin. - The plot in
Scheme 9 shows that, on average, the chelate MA_AuPr exhibits 95% of the growth inhibition activity of cisplatin. The region marked A on the plot accounts for ca. 25% of the cancer cell lines tested and confirms that a sizeable fraction of cancer cell lines are either equivalently susceptible or significantly more susceptible to MA_AuPr than to cisplatin. The complex MA_AuDM shows a similar activity profile to that of MA_AuPr (with 91% of the activity of cisplatin on average and around 12% of the cell lines being more susceptible to this Au(III) drug than to cisplatin). These data demonstrate that the new class of bis(pyrrolide-imine) Au(III) chelates of the invention should compete favorably with cisplatin or, in fact, be better for around 25% of human cancers. We have yet to test the Au(III) macrocycles 1.1Y1a, 1.1Y1b, and 1.5Y1a in the full 5-dose NCI-60 screens. However, complex 1.1Y1b has just entered this phase of the screening process and is expected to perform better than MA_AuPr if its performance in the HeLa cell line is an indicator of its more general cytotoxicity. -
Scheme 10a shows a comparison of −log(GI50) values for MA_AuPr (the best performing open-chelate Au(III) complex of this invention) with two comparable commercially available anticancer drugs (cisplatin and mitomycin) for selected human cancer cell lines (LE, leukemia; LC, lung cancer; CO, colo-rectal cancer; RE, renal carcinoma; PR, prostate cancer; BR, breast cancer). -
Scheme 10b compares the performance (specifically as the drug concentration at which 50% growth inhibition is observed) of two open-chelate gold(III) complexes of the invention with existing commercial anti-cancer drugs for selected human cancer cell lines. The average −log(GI50) values for all of the drugs over the cancer cell lines plotted are marked with an asterisk. -
Schemes - The in vitro cytotoxicities of the two non-macrocyclic gold(III) chelates of the invention shown in
Schemes - Mechanism of Action
- From the data presented above, it is clear that the compound MA_AuPr is an effective cytotoxic agent that is suitably active against multiple human cancer cell lines. Identification of the cellular target of the compound and elucidation of its biological mechanism of action are critical to the optimization of lead compounds into successful chemotherapeutic agents. There are three key parameters which define the cytotoxic activity of a compound against a given cancer cell line, namely its GI50, IC50, and LC50 values (see
Scheme 8a). One drug tested over 60 cancer cell lines affords 180 experimental data that may be compared with the same parameters for all other compounds similarly tested against the NCI's panel of 60 human cancer cell lines. Only hierarchical cluster analysis offers a tractable statistical approach to establish functional relationships between drugs with a large data set. There are various ways in which to effect hierarchical cluster analysis of a large data set. Irrespective of the method chosen, one expects to delineate which drugs exhibit similar activity profiles over the full 60 cell line panel. Compounds most similar in behavior will converge in the statistical analysis to form a tight group or cluster. If a test agent has an unknown mechanism of action and is found to cluster or fall within a group of compounds whose mechanism of action has been previously and independently determined, then one can conclude, with reasonably high certainty, that the test agent is active against the same cellular target as the majority of the compounds within a particular cluster. - Scheme 11 (below) shows a dendrogram obtained via hierarchical cluster analysis of the GI50, IC50, and LC50 values for a range of commercial anti-cancer drugs with known mechanisms of action. The Au(III) compounds of the invention were included in the analysis and are highlighted in red. It is clear from the clusters shown that the activity of MA_AuPr correlates best with that of etoposide, one of the most widely used topoisomerase II poisons. The compound also appears on a branch with a direct, though distant, link to the drugs daunorubicin and cisplatin. Daunorubicin is a potent topoisomerase II poison, while cisplatin has been shown to be an effective catalytic inhibitor25 of topoisomerase II (in addition to its role as a DNA cross-linker and guanine-N7 “alkylating” agent).
- Topoisomerase II is an essential nuclear enzyme found in all living cells. Topoisomerase II participates in various DNA metabolic processes, such as transcription, DNA replication, chromosome condensation, and de-condensation, and is essential at the time of chromosome segregation after cell division.26 This enzyme transiently creates a protein-concealed double-strand break in one DNA molecule through which a second double-stranded DNA molecule can be transported prior to religation of the DNA.26 There are two classes of compounds that act against topoisomerase II—poisons and catalytic inhibitors. The former compounds stabilize the ternary drug-enzyme-DNA cleavage complex and favor an increase in the number of DNA double strand breaks; these are highly damaging to cancer cells and lead to apoptosis (programmed cell death).27 The latter compounds (catalytic inhibitors) are either competitive inhibitors (block DNA binding), non-specific inhibitors (react with topoisomerase II sulfhydryl groups, e.g., cisplatin,25 thereby altering the proper function of the enzyme), or inhibitors that block the ATPase domain of the enzyme (effectively curtailing the ATP-dependent DNA strand passage step in the cycle). Highly successful, though highly toxic, commercial anticancer compounds active against topoisomerase II include the drugs etoposide, teniposide, doxorubicin, daunorubicin, and idarubicin.26 There are, however, difficulties associated with the use of these drugs in chemotherapy due to their high general toxicity. The cardiac toxicity of the compounds is generally high and catalytic inhibitors of topoisomerase II (such as dexrazoxane, ICRF-187) are administered along with a topoisomerase poison to temper the toxicity of the poison,28 or to prevent tissue damage (necrosis) when extravasation of a topoisomerase poison occurs during chemotherapy.29 There is also good evidence to suggest that topoisomerase poisons are themselves carcinogenic, such that the development of post-treatment (secondary) cancer occurs in some patients. 30
- The compound MA_AuPr clearly targets topoisomerase II if the statistical analysis of the NCI data for a range of drugs shown in
Scheme 11 is correct. MA_AuPr was therefore assayed for its action against topoisomerase II in vitro using TopoGEN's standard protocol over a wide range of test agent concentrations (0.005 to 500 μM) in order to obtain direct experimental proof for the apparent cellular target of the compound to ensure that a fundamental understanding of the mechanism of action of this new class of Au(III) compounds exists. These experiments were performed by the company TopoGEN and at the University of Central Florida. The DNA cleavage experiments were performed in vitro using purified topoisomerase I and II enzymes and supercoiled plasmid DNA as the substrate. The controls that were used in the experiment were linear marker DNA as well as reactions without the gold(III) complex and high concentrations of VP16. The compound VP16 (etoposide) is a commercially available DNA intercalator chemotherapeutic agent, widely used in the treatment of lung and testicular cancers as well as lymphomas. The choice of VP16 as a control is based on the fact that it is a poor topoisomerase II inhibitor, but is a powerful topoisomerase II poison which arrests the enzyme's cycle at the ternary drug-enzyme-DNA cleavage complex stage, leading to observation of linear DNA fragments upon SDS denaturation of the enzyme (i.e., work-up). Comparison of the VP16 results with the results of MA_AuPr would therefore give a good indication of whether the gold(III) chelate is an inhibitor or a poison. The results of the ethidium bromide (EB) gel analysis are shown inScheme 12. -
Lane 1 of the gel (Scheme 12) is the control experiment with only supercoiled plasmid DNA present. The control contains no topoisomerase II and so the DNA supercoiled structure cannot be relaxed, as the topoisomerase II enzyme would usually do. The gel shows that the complex MA_AuPr begins to effectively poison topoisomerase II at a concentration of 0.5 μM (lane 5 of the gel), as evidenced by the formation, trapping, and detection of linear DNA cleavage products at this concentration of the test agent. At a higher concentration of the test agent (50 μM), both supercoiled plasmid DNA and linear cleavage products are observed. This shows that MA_AuPr exhibits dual action at this concentration in that it functions both as a topoisomerase II poison (forming linear DNA) and as a topoisomerase II catalytic inhibitor (preventing relaxation of the supercoiled plasmid DNA substrate). At very high concentrations (>500 μM), MA_AuPr behaves exclusively as a catalytic inhibitor of the enzyme. - The formation of a low concentration of linear DNA (
lane 5 of the gel) demonstrates that the compound MA_AuPr has the ability to interrupt the second step of the cleavage/ligation cycle, in particular preventing religation of the double-stranded DNA. This conclusion is based on the fact that the cleavage/ligation cycle leads to formation of trapped intermediates, which resolve as linear DNA in the gels. In summation, the test compound MA_AuPr is therefore both a poison and a catalytic topoisomerase II inhibitor. - This result is particularly interesting since, in the treatment of brain cancers in mice, combinations of topoisomerase II inhibitors and poisons are often used because the efficacy of the combined treatment is greater than the sum of the parts and a catalytic inhibitor modulates the acute toxicity of the poison. Therefore, a drug that demonstrates both inhibition and poisoning of the enzyme is potentially a novel and useful chemotherapeutic agent.25
- MA_AuPr was also tested to determine if the compound was a topoisomerase I poison or inhibitor since the compound appears to be a topoisomerase II-specific agent and not a DNA intercalator with multiple enzyme targets. The results are shown in the EB gel in
Scheme 13. The gel electrophoresis experiment shows that the gold(III) chelate is not a topoisomerase I poison. This conclusion is based on comparison of the migration of the DNA with various concentrations of the gold(III) chelate with the lane containing CPT (camptothecin, a topoisomerase-I specific poison) and linear DNA as a reference or marker. This result shows that the gold(III) chelate specifically poisons topoisomerase II and not topoisomerase I. - The role of gold(III) in the efficacy of the compound was determined by modifying the structure of MA_AuPr by replacing the Au(III) cation with Pd(II) to afford MA_PdPr (the isoelectronic square planar coordination complex of known structure and geometry31) and carrying out the DNA relaxation assay with topoisomerase II as before. The metal-free ligand (MA_H2PrLig) was tested under identical conditions to confirm that the mechanism of action is related to the intact structure of the metal chelate. The results are shown in
Schemes - The data confirm firstly that the free ligand is not a good topoisomerase II poison. Secondly, The efficacy of the Au(III) chelate is 100 times higher than that of the isoelectronic Pd(II) chelate. This result is expected and is consistent with the electrophilic character of the Au(III) ion, which is known to favor electrostatic interactions with aromatic groups or anions perpendicular to the square planar coordination group (i.e., the vacant axial interaction sites at the metal center). Compound 1a is also positively charged, whereas the Pd(II) chelate is neutral and thus likely to exhibit diminished electrostatic attraction for the phosphate backbone of double-stranded DNA.
- The topo II inhibition assay for the Au(III) macrocycle KA_AumacroPr is shown above in
Scheme 16. In contrast to MA_AuPr, this complex functions as a pure catalytic inhibitor of topo II since no trapped linear DNA cleavage products are evident that would signal behavior of the complex as a topo II poison. The enzyme inhibition is characterized by an IC50 of 4.8 μM, which is in excellent agreement with the cell cytotoxicity IC50 value measured for this compound against HeLa cells (Scheme 8b). - As indicated by the DNA unwinding assay in
Scheme 17, the test agent KA_AumacroPr interferes with the normal operation of human topoisomerase I. Specifically, abnormal relaxation products are generated from supercoiled plasmid DNA. This is consistent with strong intercalative binding of KA_AumacroPr to the plasmid DNA probably before and after the action of topoisomerase I, and consequently inhibition of its normal turnover cycle. Collectively the data inSchemes - For a drug to act as a topoisomerase II poison, two molecular recognition events must occur. Firstly, the drug must bind to DNA via intercalation between base pairs and secondly, the drug must interact with topoisomerase II in such a way that religation of the DNA after formation the topoisomerase II-DNA covalent complex (the catalytic intermediate) is impossible. The enzyme is poisoned at this point and the cycle irreversibly disrupted by the drug.
Scheme 18 shows titration data for the titration of complex 1.1 a with calf-thymus DNA (ctDNA). - The hypochroism of the absorption band of the complex at 383 nm was monitored as a function of added ctDNA. The data were fitted to equation (1)32 to determine the affinity constant by non-linear regression:
-
(εa−εf)/(εb−εf)=(b−(b 2−2K a 2 Ct[DNA]/s)1/2)/2K a Ct (1a) -
b=1+K a Ct+K a[DNA]/2s (1b) - where [DNA] is the concentration of DNA base pairs, εa is the extinction coefficient (Aabs/[M]) observed for the 383-nm MLCT absorption band of MA_AuPr at a given DNA concentration, εf and εb are the extinction coefficient for the free Au(III) complex and the extinction coefficient for the Au(III) complex in the fully bound form, respectively. Ka is the equilibrium binding constant in M−1, Ct is the total Au(III) complex concentration, and s is the binding site size.
- From
Scheme 18, it is clear that compound 1.1a binds to ctDNA with a high affinity constant. Moreover, since the MLCT (metal-to-ligand-charge-transfer) band of the complex at 383 nm decreased upon DNA binding (hypochroism), the mode of interaction is likely to be intercalation, as occurs with Ru(II) complexes with known DNA-intercalating bidentate ligands. -
Scheme 19Summary of selected calf thymus DNA binding constants for open- and macrocyclic Au(III) chelates. Complex Ka (calf thymus DNA)/ M−1 Cytotoxicity# 1.1a (MA_Au Pr) 2.05(2) × 105 active 1.1b (MA_AuDM) 1.63(3) × 105 active 1.1c (MA_AuOH) 1.43(3) × 105 in vitro only 1.1d (MA_AuOEt) 1.01(4) × 106 active 1.1e (MA_AuCI) 3.91(7) × 105 active 1.1Y1a (KA_Aumacro Pr) 2.8(2) × 106 active 1.1Y1b (KA_AumacroDM) 1.49(8) × 106 active 1.5Y1a (KA_AumacroBu) 1.20(9) × 106 active Conditions: MA series of complexes in pH 7.0 phosphate buffer at 37° C. KA series of complexes in pH 7.0 15% DMSO-TRIS buffer at 25° C. #Active: mean IC50 value in low μM range in the NCI-60 cytotoxicity screen or in an independent cytotoxicity screen. In vitro: the compound is a proven too II poison in vitro (cell-free enzyme assay). -
Scheme 19 summarizes the DNA affinity constants for the compounds. The affinity constants are high (105 to 106 M−1) and the data clearly show, in unison withScheme 18, that both the non-macrocyclic and macrocyclic Au(III) complexes are DNA intercalators. Consequently, the compounds are capable of disrupting the topoisomerase I or II DNA religation step and/or its ability to bind DNA (competitive inhibition). In short, the compounds of this invention act as poisons and/or inhibitors of the human topoisomerase I and/or II enzyme in vitro. - Key to the design of compounds for cancer chemotherapy is an early assessment of their toxicology profiles. Compounds have to be well-tolerated in live subjects, easily metabolized or excreted, well-transported across cell membranes, and have favorable plasma stability to be worthy of detailed pre-clinical animal model studies.
-
Scheme 20Summary of key in vitro ADME-Tox (absorption, distribution, metabolism, toxicology) data for MA_AuPr. Test Key Indicator Comment Microsomal clearance t1/2 < 10 min Highly metabolized; low liver toxicity expected Plasma half-life t1/2 < 20 min Highly metabolized Plasma protein No binding - drug Unstable in plasma; requires binding undetected encapsulation for transport Genotoxicity Negative Non-mutagenic Cytotoxicity Strong positive Good cytotoxicity expected (Hep-G2) (consistent with NCI-60 screens of drug) Caco-2 Not an efflux Favorable intestinal uptake transporter expected substrate - The most promising non-macrocyclic Au(III) complex, MA_AuPr, was selected for in vitro ADME-Tox profiling to gauge the potential of the compound for pre-clinical animal toxicology testing and further development towards phase I human trials. The data are summarized in
Scheme 20, which reveals a number of positive attributes for the compound. First, the compound is not genotoxic (i.e. mutagenic). This means the invented compounds have a clear advantage over topo II poisons such as daunorubicin and its derivatives which are known to be genotoxic but are in clinical use. Second, the compound is rapidly metabolized by liver cytochrome P450 enzymes and hepatotoxicity is not anticipated. Third, the Hep-G2 cytotoxicity assay confirmed the expected good cytotoxicity displayed in the NCI-60 screen of the compound. Fourth, the Caco-2 transport data clearly demonstrate that the test agent is not an efflux transporter substrate and has the ability to freely pass across a monolayer of Caco-2 cells (a model for the human small intestine wall or mucosa) without much preference for direction. The Caco-2 data are especially important as many drugs fail due to poor membrane transport/absorption. The transport rates for MA_AuPr are summarized in Scheme 21. -
Scheme 21 Summary of Caco-2 transport for MA_AuPr, ranitidine (a substrate for efflux transporter proteins), and warfarin (a non-substrate for efflux transporters). mean mean Assay A→B B→A Test Conc. Duration Papp Papp Efflux Cpd. (uM) (h) (10−6 cm s−1) (10−6 cm s−1) Ratio Ranitidine 10 2 0.7 2.3 3.3 Warfarin 10 2 37.0 8.0 0.2 MA_AuPr 10 2 4.0 9.0 1.2 - The only possibly concerning ADME-Tox result shown in
Scheme 20 is that the test compound did not bind to plasma protein and was, in fact, not identified in a structurally intact form by LC-MS in the protein-free fraction (i.e. the molecular ion peak for MA_AuPr was not detected in the mass spectrum). The t1/2 of MA_AuPr in plasma was <20 min. This suggests fast conversion of the compound to another species in the presence of plasma constituents and could suggest covalent interaction with proteins or metal ion aquation/hydrolysis possibly by enzyme action. Experiments in our lab with compound 1.2a (MA_AuEt, in which W =W2, R and R1-R4 are H, Y=2H, and Z and Z1=C) have shown that water may displace a pyrrole ring from the Au(III) ion to form a Au(III)—OH species and protonated pyrrole ring. MA_AuPr did not show hydrolysis in phosphate buffered aqueous solutions presumably because the 6-membered chelate ring leads to a more stable chelate for Au(III). This is why binding to DNA of the intact chelate occurs (Schemes 12 and 18). However, it is noteworthy that hydrolysis of a Au(III)—Npyrrole bond is a reaction that may be catalyzed by enzymes in plasma and could account for the plasma instability of MA_AuPr. By way of comparison, the plasma half-life of cisplatin measures 0.88 h or ca. 53 min, while that of its mono(aqua) complex is 0.26 h (16 min).33 The plasma stability of MA_AuPr is thus very similar to that of the mono(aqua) cisplatin derivative (cisplatin is one of the most successful anticancer drugs in the history of cancer chemotherapy). - The Applicant is of the firm opinion that encapsulation of the non-macrocyclic Au(III) compounds belonging to Formula (I) in γ-cyclodextrin or other water-soluble encapsulating agents such as curcubit-[8]-uril will permit increased plasma half-lives for these compounds. Encapsulation for metallo-drug transport and stabilization is well-established in the literature,34 and has been shown to enhance the redox and plasma stability of cisplatin analogues.34 It should be noted that enhanced plasma stability for the macrocyclic Au(III) complexes belonging to Formula (I) is anticipated because hydrolysis of the Au—N pyrrole bonds in the macrocycle is quite unlikely. Experiments investigating this concept further are currently underway in our laboratory.
-
Scheme 22 Summary of cell health parameters for HepG2 human hepatocellular carcinoma cells exposed to serial dilutions of MA_AuPr and chlorpromazine (control). MA_AuPr Chlorpromazine (control) MEC MEC Cell Health Parameter (μM) AC50 (μM) MEC AC50 (μM) AC50 (μM) MEC AC50 Cell Loss <0.23 7.4 x 100 7.8 Nuclear Area 6.2 17 >11 100 DNA structure >19 N/ A 11 196 Membrane permeability 2.1 16 x 11 30 Mitochondrial mass 2.1 41 x 3.7 5.4 x x Mitochondrial membrane 6.2 >500 x 3.7 50 x potential Cytochrome C release 19 33 11 16 MEC: Minimum effective concentration that significantly crosses vehicle control threshold. N/D: Not determined due to lowest concentration tested is the returned MEC. AC50: The concentration at which 50% maximum effect is observed for each cell health parameter. N/A: The response was not significantly above control to determine an AC50 value. First Signal (x): The cell health feature which responds at the lowest observed dose. - The data for MA_AuPr in Scheme 22 are consistent with a cytotoxic compound capable of inducing apoptosis (programmed cell death) and, indeed, a compound that performs better than the control drug. The lowest MEC response data indicate that the compound MA_AuPr has resulted in an increase in membrane permeability (indicating general cell death), an increase in mitochondrial mass (indicating an adaptive response to cellular energy demands), and an increase in mitochondrial potential (implying adaption to cellular energy requirements). Other cell health parameters which respond are a loss of total cells per well (indicating toxicity due to necrosis, apoptosis or a reduction in cellular proliferation), an increase in nuclear area (indicating necrosis or G2 cell cycle arrest), an increase in cytochrome c release (implying activation of a signalling cascade leading to apoptosis). The latter is particularly relevant as we may rule out cell death by necrosis in the case of MA_AuPr. The mechanism of action of the compound thus leads to cell cycle arrest in the G2 phase and the induction of apoptosis (highly desirable for an anticancer drug). The lowest AC50 response indicates that the compound MA_AuPr has resulted in a loss of total cells per well (indicating toxicity due to necrosis, apoptosis or a reduction in cellular proliferation). Since the compound induces cytochrome c release, cytotoxicity involves apoptosis.
- The plasma stability and cytotoxicity of a test drug may be examined more extensively in an animal model (in vivo).
-
Scheme 23 shows a graph of 3 LL tumor growth (measured by caliper methods at the University of Strasbourg, France) in black mice over a 20-day period at the indicated doses. (The 3LL cell line is a solid Lewis lung carcinoma cell line of the mouse.) The compound MA_AuPr, despite its modest plasma stability in vitro (Scheme 20) and poor performance against human lung carcinoma cell lines in the NCI-60 screen (Scheme 6a), clearly slows down the growth rate of 3 LL tumors in black mice by about 33% relative to the control after 20 days. In comparison to cisplatin, which reduces the growth rate of 3LL tumors by 76% in 20 days and is a highly effective drug against lung carcinoma cell lines, MA_AuPr has about 43% of the in vivo performance of cisplatin for this particular cancer cell line. We note that the gold(III) chelates of this invention out-perform cisplatin for several colorectal carcinoma cell lines, renal carcinomas, and breast cancer cell lines (Scheme 10), so that the data presented inScheme 23 may be taken as a lower limit of the compound's in vivo cytotoxicity. The value of the experimental data shown inScheme 23 clearly lies in the fact that it demonstrates that MA_AuPr has sufficient plasma stability in live animals to exert a positive cytotoxic effect leading to reduced tumor growth rates, even for a class of tumors for which the compound is expected to perform poorly. - The results are most encouraging and suggest that xenografts of human tumor cell lines susceptible to MA_AuPr (e.g. colon carcinoma cell lines) in mouse model subjects are likely to prove illuminating and worth the cost. Furthermore, the Applicant anticipates that the most cytotoxic macrocyclic Au(III) complexes, e.g., compound 1.5Y1a, may have good plasma half-lives due to their enhanced redox stability and resistance to hydrolysis such that better time-dependent tumor growth profiles are quite likely for the macrocyclic members of Formula (I) of the invention.
-
Scheme 24 shows a set of survival data for five groups of four mice receiving from 1 to 30 μmol/kg doses of MA_AuPr. A single dose of the compound was administered by injection over the first week followed by two injections per week per mouse for a total period of 50 days. All of the mice remained healthy and showed no abnormal weight changes over the timeframe of the experiment (mouse mass data not shown, but available as a time dependent plot). The results demonstrate that MA_AuPr has an acute toxicity >30 μmol/kg/week and a chronic toxicity >60 μmol/kg/week. This is fully consistent with the ADME-Tox data (Scheme 20) which showed that the compound is highly metabolized by liver microsomes. - In conclusion, the ADME-Tox and in vivo toxicology data for MA_AuPr are complementary and collectively indicate that:
- MA_AuPr is a cytotoxic metal complex (a topoisomerase II poison and inhibitor) with a mean in vitro IC50 value in the low μM range.
-
- MA_AuPr is not genotoxic.
- MA_AuPr induces apoptosis in cancer cells such as HepG2.
- MA_AuPr is not a substrate for the efflux transporters in a Caco-2 cell monolayer and exhibits facile bidirectional transfer across this mucosal membrane mimic.
- MA_AuPr is readily metabolized by liver microsomes.
- MA_AuPr has a short plasma half life (t1/2<20 min) which is similar to the mono(aqua) derivative of cisplatin, [PtCl(NH3)2(OH2)]+.
- MA_AuPr is cytotoxic in a live animal setting (mice) and demonstrates the ability to reduce tumor growth rates for mouse lung carcinoma cells (despite having poor cytotoxicity in general for lung tumor cell lines).
- MA_AuPr is non-toxic to healthy black mice exhibiting acute and chronic toxicity values >30 μmol/kg/week and >60 μmol/kg/week, respectively.
-
- The general synthetic procedure for the synthesis of all non-macrocyclic ligands in this invention involves the condensation of two equivalents of 1H-pyrrole-2-carbaldehyde or 5-methyl-1H-imidazole-4-carbaldehyde with an appropriate 1,2- or 1,3-diaminoalkane linker unit, which forms a diiminoalkane bridge in the Schiff base condensation product. The bis(imine) compounds produced from such condensation reactions are then purified and reacted with a gold(III) salt in a suitable solvent system to form a relatively planar chelate of gold(III).
- The synthetic procedure for macrocyclic gold(III) chelates required, in most cases, the initial reaction of 2,3-bis(5′-formylpyrrol-2′-yl)quinoxaline with a gold(III) salt to form an intermediate metal chelate in which the formyl oxygen atoms and deprotonated pyrrole nitrogen atoms function in unison as a tetradentate chelating ligand and most likely form a gold(III) chelate with a AuN2O2 coordination group. This intermediate is not isolated but condensed in situ with a 1,3- or 1,4-diaminoalkane linker unit, which, through the formation of a pair Au-bound imine groups and concomitant loss of two molar equivalents of water, cyclizes the ligand to form the product Au(III) macrocycle as a monocationic complex.
- Commercially available diaminoalkanes were purchased from Aldrich and used without further purification. Commercially unavailable 1,3-diamines such as 2-ethoxy-1,3-diaminopropane and 2-chloro-1,3-diaminopropane were synthesized by t-boc protection of the two amino groups of 1,3-diamino-2-hydroxypropane followed by reaction of the hydroxy group and subsequent deprotection of the amino groups. Thus, although the compounds 2-ethoxy-1,3-diaminopropane and 2-chloro-1,3-diamino-propane are themselves not novel, with several synthetic approcahes available from the literature,35,36 the method we have employed to make them (as dihydrochloride salts) from t-boc-protected 1,3-diamino-2-hydroxypropane and to use them in subsequent condensation reactions to form diimines is novel.
- Synthetic details for making key synthons for subsequent preparation of the chelating ligands described herein are given below.
-
- Sodium hydrogencarbonate (8.3 g, 99 mmol) was dissolved in 1:1 acetonitrile:water mixture (190 mL) and the solution cooled to 4° C. in an ice bath. 1,3-diamino-2-hydroxypropane (2.5 g, 27 mmol) and di-tert-butyldicarbonate (12.8 g, 59 mmol) were dissolved in the same solvent system (65 mL). This mixture was then added to the chilled sodium hydrogencarbonate solution and stirred on ice for two hours. The reaction was then heated to room temperature and stirred overnight. The acetonitrile was removed by rotary evaporation and the protected amine extracted into dichloromethane (3×75 mL portions). The organic portions were combined, dried over sodium carbonate, and evaporated to dryness by rotary evaporation.37 The resulting oil was re-crystallised from diethylether/hexane,38 giving colourless crystals (7.2 g, 91% yield). The compound was characterised by 1H and 13C NMR and FT-IR spectroscopy. IR (cm−1): 3316 m br v(OH and NH), 2971 m and 2930 m v(CH3 and CH), 1681 s v(C═O). 1H NMR (400 MHz, CDCl3, 298 K) [δ, ppm]: 1.45 (s, 18H, H-1), 3.20 (m, 4H, H-5), 3.75 (m, 2H, H-6 and H-7), 5.20 (s br, 2H, H-4). 13C NMR (100 MHz, CDCl3, 298K) [δ, ppm]: 28.55 (C-1), 43.72 (C-2), 71.07 (C-5), 79.87 (C-6), 157.24 (C-3).
-
- N,N′-di-t-boc-2-hydroxy-1,3-diaminopropane (2.0 g, 6.9 mmol) and [Bu4N][HSO4] (0.44 g, 1.3 mmol) were dissolved in toluene (7.5 mL). To this 50% aqueous NaOH (7.5 mL) and ethyl iodide (1.67 mL, 20.7 mmol) were added. The resulting biphasic solution was heated to 100° C. for 18 hours. The solution was diluted with water and the alkylated compound extracted into ethylacetate (75 mL); this solution was washed with brine and then water and dried over anhydrous Na2CO3. The solvent was then removed by rotary evaporation and the resulting oil purified by column chromatography on silica gel using 1:4 ethylacetate:hexane as the eluent.39 The solvent in the column fractions containing the alkylated product was removed by rotary evaporation and the resulting oil was dissolved in methanolic HCl (1.25 M, 30 mL) and stirred overnight. 2-ethoxy-1,3-diaminopropane dihydrochloride precipitated as an oil from the methanol solution with the addition of diethylether. The oil was separated from the methanol by centrifugation and dried over P2O5 to give the hydrochloride salt as a white powder (0.70 g, 53% yield). The powder was characterised by 1H NMR. 1H NMR (400 MHz, D2O, 298 K) [δ, ppm]: 1.24 (t, 3H, H-1), 3.14 (dd, 2H, 3J1=7.13 Hz, 3J2=14.2 Hz, H-4), 3.35 (dd, 2H, 3J1=4.3 Hz, 3J2=13.0 Hz, H-4), 3.69 (q, 2H, H-2), 4.03 (m, 1H, H-3).
-
- N,N′-di-t-boc-2-hydroxy-1,3-diaminopropane (1.0 g, 3.5 mmol) and triphenylphosphine (1.5 g, 5.72 mmol) were dissolved in chloroform (15 mL) and carbon tetrachloride (35 mL). This solution was refluxed for 5 hours, before the solvents were removed under reduced pressure by rotary evaporation. The resulting oil was dissolved in diethylether to precipitate the OPPh3 and the resulting solution centrifuged to remove the insoluble OPPh3. The diethyl ether was removed by rotary evaporation and the resulting oil dissolved in methanolic HCl (1.25 M, 30 mL) and stirred overnight. The 2-chloro-1,3-diaminopropane dihydrochloride was precipitated as a white powder by the addition of dichloromethane. The powder was stored over P2O5 (0.304 g, 49% yield). The complex was characterised by 1H and 13C NMR spectroscopy. 1H NMR (400 MHz, D2O, 298 K) [δ, ppm]: 3.34 (dd, 2H, 3J1=3.8 Hz, 3J2=14.7 Hz, H-2), 3.57 (dd, 2H, 3J1=3.3 Hz, 3J2=13.9 Hz, H-2), 4.58 (m, 1H, H-1). 13C NMR (100 MHz, D2O, 298K) [δ, ppm]: 42.95 (C-2), 54.94 (C-1).
- General Synthesis of Simple bis(pyrrole-imine) and bis(imidazole-imine) Ligands
- 1H-Pyrrole-2-carbaldehyde (30 mmol) or 5-methyl-1H-imidazole-4-carbaldehyde (30 mmol) and a 1,2- or 1,3-diaminoalkane derivative (15 mmol) were refluxed in ethanol (30 mL) for two hours. During refluxing the reaction mixture changed from colourless to a clear, bright orange. Solvent was then removed by rotary evaporation, leaving a viscous orange-coloured oil. The oil was then dissolved in dichloromethane prior to adding hexane to the solution, which was left to re-crystallise overnight. This typically yields the crystalline bis(Schiff base) product in around 70-90% yield. The crystalline product can be shown to be clean by thin layer chromatography or 1H NMR spectroscopy. Single crystals suitable for X-ray crystallography may also be obtained from the re-crystallisation process. The procedure and full characterization for N,N′-bis[(1E)-1H-pyrrol-2-ylmethylene]propane-1,3-diamine have, for example, been reported elsewhere.14
- The general strategy when condensing dihydrochloride salts of the diamine linker group with two molar equivalents of 1H-pyrrole-2-carbaldehyde was to carry out the reaction under solvent-free conditions to avoid incompatible solubility of the two reagents and to obviate the use of organic bases for deprotonation of the diamine reagent's ammonium groups. A typical solid-state reaction is described below.
- Excess sodium carbonate (ca. 4 mmol) and a relevant 2-substituted 1,3-diaminopropane dihydrochloride derivative (ca. 2 mmol) were ground in an agate pestle and mortar for 1 minute. To the resulting white paste, 1H-pyrrole-2-carbaldehyde (ca. 4 mmol) was added and the mixture ground together for a further 10 min. Water was then added to the paste, followed by acetone, to dissolve the ligand. The solvent solution was collected and the acetone allowed to evaporate, yielding the ligand as a pale yellow powder. The powder was purified by re-crystallisation from 1:30:50 ethanol:THF:hexane. Typical isolated yields were of the order of 60-70%. The product ligands were analysed by 1H NMR, 13C NMR, UV/visible and IR spectroscopy. In some cases, crystals suitable for a structure determination by X-ray diffraction were obtained during the re-crystallisation step. Synthetic methods and characterization data for several novel ligands prepared in this way are described below.
-
- Sodium carbonate (0.448 g, 4.24 mmol) and 2-chloro-1,3-diaminopropane dihydrochloride (0.350 g, 1.93 mmol) were ground in an agate pestle and mortar for 1 minute. To the resulting white paste, 1H-pyrrole-2-carbaldehyde (0.365 g, 3.93 mmol) was added and the mixture ground together for a further 10 min. Water was then added to the paste, followed by acetone, to dissolve the ligand. The solvent solution was collected and the acetone allowed to evaporate, yielding the ligand as a pale yellow powder. The powder was re-crystallised from 1:30:50 ethanol:THF:hexane (0.290 g, 62% yield). The novel ligand was further characterized by 1H NMR, 13C NMR, UV/visible and IR spectroscopy. UV/vis (ethanol) [λmax, nm; ε, mol−1 dm3 cm−1]: 292; 3.81×104. IR (cm−1): 3183 w δ(NH, pyrrole), 2942 m br v(CH, imine), 2838 m v(CH, H—CCl), 1643 s br v(C═N), 743 (C—Cl stretch). 1H NMR (400 MHz, DMSO-d6, 298 K) [δ, ppm]: 3.74 (dd, 3J1=7.2 Hz, 3J2=5.3 Hz, 2H, H-6), 4.01 (dd, 3J1=7.88 Hz, 3J2=5.3 Hz, 2H, H-6), 4.45 (m, 1H, H-7) 6.13 (t, 2H, H-2), 6.50 (dd, 3J1=3.7 Hz, 3J2=1.3 Hz, 2H, H-3), 6.90 (s br, 2H, H-1), 8.11 (s, 2H, H-5), 11.37 (s br, 2H, CD3OD exchangeable, H-8). 13C NMR (100 MHz, DMSO-d6, 298 K) [6, ppm]: 63.57 (C-6), 64.88 (C-7), 109.47 (C-2), 114.53 (C-3), 122.96 (C-1), 129.98 (C-4), 154.43 (C-5).
-
- Sodium carbonate (0.366 g, 3.45 mmol) and 2-ethoxy-1,3-diaminopropane dihydrochloride (0.300 g, 1.57 mmol) were ground together in an agate pestle and mortar for 5 min. To the resulting white paste, 1H-pyrrole-2-carbaldehyde (0.299 g, 3.14 mmol) was added and the mixture ground for a further 10 min. The crude ligand was dissolved in dichloromethane (40 mL) and washed with water (3×25 mL) portions. The organic layer was dried over anhydrous sodium carbonate. To the dichloromethane solution, aliquots of ethanol (1 mL) and hexane (50 mL) were added to re-crystallise the ligand. Crystals suitable for singe crystal X-ray diffraction were obtained from the re-crystallisation (0.280 g, 65% yield). The novel ligand was further characterized by 1H NMR, 13C NMR, UV/visible and IR spectroscopy and X-ray diffraction. UV/vis (ethanol) [λmax, nm; ε, mol−1dm3cm−1]: 290; 3.48×104. IR (cm−1): 3158 w δ(NH, pyrrole), 2975 m br v(CH, imine), 2901 m v(CH, H—COCH2), 2838 m v(CH, CH3) 1631 s br v(C=N), 734 (C—O stretch). 1H NMR (400 MHz, CDCl3, 298 K) [δ, ppm]: 1.08 (t, 3H, H-9), 3.49-3.65 (m, 4H, H-6), 3.65-3.80 (m, 3H, H-8), 6.21 (t, 2H, H-2), 6.46 (dd, 3J1=3.7 Hz, 3J2=1.3 Hz, 2H, pyrrole H-3), 6.86 (s br, 2H, H-1), 8.03 (s, 2H, H-5), 9.53 (s, 2H, CD3OD exchangeable, H-10). 13C NMR (100 MHz, CDCl3, 298 K) [δ, ppm]: 15.62 (C-9), 62.64 (C-6), 65.82 (C-8), 79.31 (C-7), 109.66 (C-2), 114.34 (C-3), 122.02 (C-1), 130.26 (C-4), 153.68 (C5).
- There are several methods in the literature for making [Bu4N][AuCl4]. We have developed a modified version of a typical method which involves precipitation of [Bu4N][AuCl4] after the addition of [Bu4N]Cl to a solution of H[AuCl4].40 More specifically, we found it necessary to add a solvent-extraction step to the preparative method to obtain an acid-free product suitable for subsequent metallation reactions of the potentially hydrolysable Schiff base ligands described in this invention.
- Hydrogen tetrachloroaurate(III) (0.406 g, 0.98 mmol) was dissolved in deionised water (15 mL). To this solution tert-butylamonium hydrogen sulphate (340 mg, 1.01 mmol) was added, forming a lipophillic gold(III) salt, which immediately precipitated from the aqueous solution as a bright yellow powder:
-
H[AuCl4](aq)+[Bu4N][HSO4](aq)→[Bu4N][AuCl4](s)+H2SO4(aq) - The [Bu4N][AuCl4] was then extracted from the sulphuric acid into chloroform. The organic solution was dried over magnesium sulphate before the chloroform was removed by rotary evaporation, leaving a bright yellow, crystalline solid (0.570 g, 97.2% yield). The crystalline solid was dried under vacuum and stored under nitrogen.
- General Metallation of Simple bis(pyrrole-imine) and bis(imidazole-imine) Ligands
- In a typical reaction carried out under an inert atmosphere, [Bu4N][AuCl4] (100 mg, 0.172 mmol) was added to a dry 100 mL round-bottom flask and dissolved in 20 mL of dry dichloromethane. Five molar equivalents of free base ligand (0.860 mmol) were dissolved in 15 mL of dry ethanol. The ethanolic solution was then heated and the gold(III) solution was added via cannula transfer to the hot ethanol solution and the mixture stirred under nitrogen. The solution rapidly turned a deep red colour and the product precipitated from the solution as a pale yellow powder after approximately 45 minutes. The precipitate was collected by centrifugation. This crude material was re-crystallized by slow liquid diffusion of a methanol solution of the complex into diethylether. The re-crystallized product may be isolated in 60-70% yield and analysed by X-ray crystallography as well as LCMS, NMR, IR and UV/visible spectroscopy.
- Specific Synthetic Procedure for Compound 1.1a
- The synthetic scheme (
Scheme 26 below) and structures of the reagents and products are shown below for MA_AuPr. The method is general for all of the non-macrocyclic bis(pyrrolide-imine) structures listed in Formula (I). - The following reaction was carried out under inert atmosphere conditions. To a dry 100 mL round-bottomed flask, [Bu4N][AuCl4] (100 mg, 0.172 mmol) was added and dissolved in 20 mL dry dichloromethane. Five molar equivalents of free base ligand (196 mg, 0.860 mmol) was dissolved in 15 mL of dry ethanol (the ligand was synthesized as previously described14). The ethanolic solution was then heated and the gold(III) solution was added via cannula transfer to the hot ethanol solution and the mixture stirred under nitrogen. The solution rapidly turned a deep red color and the product precipitated from the solution as a pale yellow powder after approximately 45 minutes. The precipitate was now air stable and was collected by centrifugation. This crude material was re-crystallized by slow liquid diffusion of a methanol solution into diethylether. The re-crystallized product (52.8 mg, 0.148 mmol, 67% yield) was shown to be MA_AuPr by X-ray crystallography as well as NMR, IR and UV/visible spectroscopy.
- It was found that use of a smaller excess of ligand resulted in the desired chelate. The counterion of this chelate was not, however, the desired chloride ion but rather a linear gold(I) chloride, [AuCl2]−. The presence of this undesirable anion was confirmed by X-ray crystallography. The developed method with the addition of the gold(III) solution to the excess ligand, dissolved in hot ethanol consistently produced the desired chelate, with the desired anion.
- The salt [Bu4N][AuCl4] was found to be more satisfactory than the more conventional [Na][AuCl4] as the source of gold(III) ions for two reasons. First, the use of [Na][AuCl4] resulted in the formation of [AuCl2]−anions, regardless of the concentration of the ligand solution. Second, the salt [Bu4N][AuCl4] is soluble in non-polar solvents, unlike [Na][AuCl4] which is only soluble in polar solvents. This therefore means that the chelation reaction can be carried out in non-polar solvents. This is ideal since the starting materials are soluble in non-polar solvents, while the gold(III) chelate is not. The gold(III) chelate therefore precipitates out of solution relatively pure. This synthetic method was therefore found to require no additional purification steps, the final crystallization was sufficient to generate a high purity material.
- Characterization Data for Compound 1.1a
- 2,2′-{propane-1,3-diylbis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) chloride: M/Z+=423.0885 M+ (calc.=423.0884). UV/vis (methanol) [λmax, nm; ε, mol−1 dm3 cm−1]: 288; 1.47×104, 382; 1.05×104. IR (KBr pellet, cm−1): 3090 m br v(CH, imine), 3010 m v(CH, CH2CH2CH2), 2930 m v(CH, CH2—N═CH), 1590 s br v(C═N). 1H NMR (400 MHz, CD3OD, 298 K) [δ, ppm]: 2.28 (q, 2H, CH2CH2CH2), 3.78 (t, 4H, CH2-N═CH), 6.49 (dd, 3J1=2.5 Hz, 3J2=2.5 Hz, 2H, pyrrole β-H), 7.05 (d, 2H, pyrrole γ-H), 7.58 (d br, 2H, pyrrole α-H), 8.22 (s, 2H, imine). 13C NMR (100 MHz, CD3OD, 298 K) [δ, ppm]: 32.53 (CH2CH2CH2), 52.95 (CH═NCH2), 113.96 (pyrrole β-C), 124.39 (pyrrole γ-C), 138.32 (pyrrole C NH—C—C═N), 139.25 (pyrrole α-C), 164.55 (imine C).
- Characterization Data for Compound 1.1b
- 2,2′-{(2,2-dimethylpropane-1,3-diyl)bis[nitrilo(E)methyl-ylidene]} bis(pyrrol-1-ido)gold(III) chloride: M/Z+=451.1196 M+ (calc.=451.1197). UV/vis (ethanol) [λmax, nm; ε, mol−1 dm3 cm−1]: 290; 1.48×104, 381; 1.11×104. IR (KBr pellet, cm−1): 3176 w δ(NH, pyrrole), 3125 m br v(CH, imine), 2970 m v(CH, terminal CH3), 2854 m v(CH2, alkyl), 1631 s br v(C═N). 1H NMR (400 MHz, CD3OD, 298 K) [δ, ppm]: 0.98 (s, 6H, terminal CH3), 3.43 (s, 4H, alkyl CH2), 6.26 (dd, 3J1=3.7 Hz, 3J2=1.3 Hz, 2H, pyrrole β-H), 6.45 (t, 2H, pyrrole γ-H), 6.91 (s br, 2H, pyrrole α-H), 8.02 (s, 2H, imine).13C NMR (100 MHz, CD3OD, 298 K) [δ, ppm]: 22.18 (CH3), 39.03 (C(CH3)2), 61.70 (CH═NCH2), 112.84.69 (pyrrole β-C), 123.33 (pyrrole γ-C), 137.57 (Pyrrole C NH—C—C═N), 137.95 (pyrrole α-C) 163.98 (imine C).
- Characterization Data for Compound 1.1c
- 2,2′-{(2-hydroxypropane-1,3-diyl)bis[nitrilo(E) methyl-ylidene]}bis(pyrrol-1-ido)gold(III) hexafluorophosphate(V): M/Z+=439.0834 M+ (calc.=439.0833). UV/vis (methanol) [λmax, nm; ε, mol−1 dm3 cm−1]: 282; 1.57×104, 379; 1.15×104. IR (KBr pellet, cm−1): 3431 m br δ(OH), 3110 m br v(CH, imine), 2985 m v(CH, H—COH), 2946 m v(CH, CH2—N═CH), 1592 s br v(C═N), 1104 w (C—O stretch). 1H NMR (400 MHz, D2O, 298 K) [δ, ppm]: 3.35 (s ,1H, HOCH), 3.77 (s, 2H, CH2—N═CH, 6.36 (dd, 3J1=2.1 Hz, 3J2=1.8 Hz pyrrole β-H), 6.89 (s br, 2H, pyrrole γ-H) 7.24 (s, 2H, pyrrole α-H), 8.02 (s, 2H, imine). 13C NMR (100 MHz, D2O, 298 K) [δ, ppm]: 54.95 (CH2CHOHCH2), 69.02 (CH2CHOHCH2), 100.03 (pyrrole β-C), 113.07 (pyrrole γ-C), 124.00 (pyrrole C NH—C—C═N), 137.08 (pyrrole α-C), 164.62 (imine C).
- Characterization Data for Compound 1.1d
- 2,2′-{(2-ethoxypropane-1,3-diyl)bis[nitrilo(E)methylylidene]}bis (pyrrol-1-ido)gold(III) hexafluorophosphate(V): M/Z+=467.1148 M+ (calc.=467.1146). UV/vis (acetonitrile) [λmax, nm; ε, mol−1 dm3 cm−1]: 288; 1.43×104, 379.5; 1.10×104. IR (cm−1): 2909 m br v(CH, imine), 2880 m v(CH, H—COC), 1581 s br v(C═N), 1045 s v(C—O) 834 w v(PF6). 1H NMR (400 MHz, CD3CN, 298 K) [δ, ppm]: 1.16 (t, 3H, CH3), 3.61 (q, 2H, OCH2CH3), 3.80 (d, 2H, CH2—N═CH), 3.95 (dd, 3J1=9.6 Hz, 3J2=5.8 Hz, 2H, CH2—N═CH), 4.31 (t ,1H, OCH), 6.53 (dd, 3J1=2.1 Hz, 3J2=1.8 Hz pyrrole β-H), 7.10 (s br, 2H, pyrrole γ-H) 7.54 (s, 2H, pyrrole α-H), 8.12 (s, 2H, imine). 13C NMR (100 MHz, CD3CN, 298 K) [δ, ppm]: 14.50 (CH3), 29.99 (OCH2CH3) 53.28 and 64.20 (CH2CHClCH2), 75.49 (CH), 112.85 (pyrrole γ-C), 123.59 (pyrrole C NH—C—C═N), 137.65 (pyrrole α-C), 164.36 (imine C).
- Characterization Data for Compound 1.1e
- 2,2′-{(2-chloropropane-1,3-diyl)bis[nitrilo(E)methylylidene]}bis (pyrrol-1-ido)gold(III) hexafluorophosphate(V): M/Z+=457.0497 M+ (calc.=457.0494). UV/vis (acetonitrile) [λmax, nm; ε, mol−1 dm3cm−1]: 289; 1.54×104, 381.5; 1.22×104. IR (cm−1): 3141 m br v(CH, imine), 3046 m v(CH, H—CCl), 1581 s br v(C═N), 822 w v(PF6), 741 s v(C—Cl). 1H NMR (400 MHz, CD3CN, 298 K) [δ, ppm]: 3.96 (dd, 3J1=10.00 Hz, 3J2=4.85 Hz, 2H, CH2—N═CH), 4.15 (d, 2H, CH2—N═CH), 5.00 (t ,1 H, ClCH), 6.56 (dd, 3J1=2.1 Hz, 3J2=1.8 Hz pyrrole β-H), 7.16 (s br, 2H, pyrrole γ-H) 7.57 (s, 2H, pyrrole α-H), 8.11 (s, 2H, imine). 13C NMR (100 MHz, CD3CN, 298 K) [67 , ppm]: 55.86 (CH2CHClCH2), 58.00 (CH2CHClCH2), 100.03 (pyrrole β-C), 113.28 (pyrrole γ-C), 124.52 (pyrrole C NH—C—C═N), 137.59 (pyrrole α-C), 164.65 (imine C).
- Characterization Data for Compound 1.2a
- 2,2′-{ethane-1,2-diylbis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) hexafluorophosphate(V): M/Z+=409.0728 M+ (calc.=409.0729). UV/vis (acetonitrile) [λmax, nm; ε, mol−1 dM3cm−1]: 292; 1.45×104, 385; 1.07×104. IR (KBr pellet, cm−1): 3127 m br v(CH, imine), 3053 m v(CH, CH2CH2), 2866 m v(CH, CH2—N═CH), 1575 s br v(C═N). 1H NMR (400 MHz, CD3OD, 298 K) [δ, ppm]: 4.40 (s, 4H, CH2—N═CH), 6.50 (dd, 3J1=2.14 Hz, 3J2=1.3 Hz, 2H, pyrrole β-H), 7.08 (s, 2H, pyrrole α-H), 7.47 (t, 2H, pyrrole γ-H), 7.86 (s, 2H, imine). 13C NMR (100 MHz, CD3CN, 298 K) [δ, ppm]: 62.49 (CH2CH2), 112.89 (pyrrole 13-C), 125.67 (pyrrole γ-C), 137.99 (pyrrole α-C), 138.84 (Pyrrole C NH—C—C═N), 161.44 (imine C). 31P NMR (162 MHz, CD3CN, 298 K) [δ, ppm]: −144.62 (PF6). 19F NMR (376 MHz, CD3CN, 298 K) [δ, ppm]: −73.82, −71.95 (PF6).
- Characterization Data for Compound 1.2b
- 2,2′-{(2S)-propane-1,2-diylbis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) hexafluorophosphate(V): M/Z+=423.0883 M+ (calc.=423.0884). UV/vis (acetonitrile) [λmax, nm; ε, mol−1 dm3 cm−1]: 293.5; 1.42×104, 385; 1.08×10 4. IR (KBr pellet, cm−1): 3125 w br v(CH, imine),1552 s br v(C═N), 830 s (PF6). 1H NMR (400 MHz, CD3OD, 298 K) [δ, ppm]: 1.62 (d, 3H, CH3) 4.21 (dd, 3J1=7.88 Hz, 3J2=6.5 Hz, 1 H, CH2), 4.48 (dd, 3J1=8.58 Hz, 3J2=5.81 Hz, 1H, CH2) 4.85 (m, 1H, CHCH3), 6.50 (dd, 3J1=2.14 Hz, 3J2=1.3 Hz, 2H, pyrrole β-H), 7.08 (s, 2H, pyrrole α-H), 7.47 (t, 2H, pyrrole γ-H), 7.84 (s, 1H, imine), 7.88 (s,1H, imine). 13C NMR (100 MHz, CD3CN, 298 K) [δ, ppm]: 16.18 (CH3), 68.07 (CH2), 113.03 (pyrrole (β-C), 125.58 (pyrrole γ-C), 140.00 (pyrrole α-C), 143.11 (Pyrrole C NH—C—C═N), 159.68 (imine C), 161.36 (imine C). 31P NMR (162 MHz, CD3CN, 298 K) [δ, ppm]: −144.27 (PF6). 19F NMR (376 MHz, CD3CN, 298 K) [δ, ppm]: −73.87, −71.99 (PF6).
- Characterization Data for Compound 1.3b
- 2,2′-{(4-methyl-1,2-phenylene)bis[nitrilo(E)methylylidene]}bis(pyrrol-1-ido)gold(III) nitrate(V): M/Z+=471.0887 M+ (calc.=471.0889). UV/vis (ethanol) [λmax, nm; ε, mol−1 dm3 cm−1]: 296; 2.00×104, 323; 4.03×104, 374.5; 1.58×104, 457; 1.43×104. IR (cm−1): 3097 m br v(CH, imine), 2983 m v(aromatic C—H), 1553 s br v(C═N). 1H NMR (400 MHz, CDCl3, 298 K) [δ, ppm]: 2.40 (s, 3H, CH3) 6.62-8.0 (m, 9H, aromatic C—H), 8.84 (s, 2H, imine). 13C NMR (100 MHz, CDCl3, 298 K) [δ, ppm]: 21.78 (CH3), 115.26 (pyrrole α-C), 118.04 (pyrrole (β-C), 120.35 (CH3CCHCN), 120.98 (CHCHCN) 124.68 (pyrrole γ-C), 127.25 (CHCHCN) 131.23 (pyrrole C NH—C—C═N), 143.76 (CH3C), 145.4 (Ph C), 153.33 (imine C).
- Characterization Data for Compound 1.4c
- 2,2′-{(1R,2R)-cyclohexane-1,2-diylbis[nitrilo(E)methylyliden]}bis(pyrrol-1-ido)gold(III)hexafluorophosphate(V): M/Z+=463.1195 M+ (calc.=463.1197). UV/vis (acetonitrile) [λmax, nm; ε, mol−1 dm3 cm−1]: 294; 1.54×104, 380.5; 1.22×104. IR (cm−1): 2955 m br v(CH, imine), 2867 m v(CH, CH2CH2), 1564 s br v(C═N), 821 s v(PF6). 1H NMR (400 MHz, DMSO, 298 K) [δ, ppm]: 1.31 and 1.65 (t, 2H, CH2CH), 1.78 and 2.61 (d, 2H, CH2CH2CH), 4.32 (d, 2H, CH) 6.47 (dd, 3J1=2.14 Hz, 3J2=1.3 Hz, 2H, pyrrole β-H) ), 7.07 (t, 2H, pyrrole α-H), 7.78 (s br, 2H, pyrrole γ-H), 8.37 (s, 2H, imine). 13C NMR (100 MHz, DMSO, 298 K) [δ, ppm]: 24.40 (CHCH2CH2CH2), 29.08 (CHCH2CH2CH2), 76.86 (CHCH2CH2CH2), 113.02 (pyrrole α-C), 125.20 (pyrrole β-C), 140.00 (pyrrole γ-C), 143.38 (Pyrrole C NH—C—C═N), 158.92 (imine C).
- Procedure for Compound 1.1f
- A solution of tert-butylammonium tetrachloroaurate (100 mg, 0.172 mmol) and tert-butylammonium hexafluorophosphate(V) (400 mg, 0.103 mmol) in dichloromethane (20 ml) was added to N,N′-bis[(1E)-(5-methyl-1H-imidazol-4-yl)methylene]propane-1,3-diamine (246 mg. 0.860 mmol) in ethanol (10 mL). A yellow precipitate immediately formed. The solution was stirred at room temperature for 1 hour. The yellow precipitate of 4, 4′-{propane-1,3-diylbis[nitrilo(E)methylylidene]}bis(5-methylimidazol-1-ide)gold(III) hexafluorophosphate(V) (complex 1.1f) was filtered and dried (81 mg, 79%). 1H NMR: (500 MHz, DMSO-d6) δ 2.22 (br, 2H, h), 2.52 (s, 6H, d), 3.74 (br, 4H, g), 8.41 (s, 2H, a), 8.83 (s, 2H, f). 13C NMR: (125 MHz, DMSO-d6) δ 14.5 (d), 30.5 (h), 51.9 (g) , 134.5 (c), 147.6 (a) , 152.7 (e), 162.0 (f). IR (cm−1): 1595(s), 1359(m), 1298(m), 1256(m), 1201(m), 1157(m), 971(w), 820(vs), 641 (m), 555(s), 482(m), 431 (m); MS: m/z 453.1099 (M+Na)+.
- Procedure for Compound 1.1g
- A solution of tert-butylammonium tetrachloroaurate (100 mg, 0.172 mmol) and tert-butylhexafluorophosphate(V) (400 mg, 0.103 mmol) in dichloromethane (20 mL) was added to a 2,2-dimethyl-N,N′-bis[(1E)-(5-methyl-1H-imidazol-4-yl)methylene]propane-1,3-diamine (178 mg, 0.688 mmol) in ethanol (5 mL). This resulted in the immediate formation of a yellow precipitate. The reaction mixture was stirred for one hour at room temperature. The yellow precipitate of 4,4′{(2,2-dimethylpropane-1,3-diyl)bis-[nitrilo(E)methylylidene]}bis(5-methylimidazol-1-ide)gold(III) hexaflurophosphate(V) (complex 1.1 g) was filtered and dried (89 mg, 83%). 1H NMR: (500 MHz, DMSO-d6) δ 1.08 (s, 6H, i), 2.53 (s, 6H, d), 3.47 (s, 4H, g), 8.45 (s, 2H, a), 8.80 (s, 2H, f). 13C NMR: (125 MHz, DMSO-d6) δ 14.5 (d), 30.5 (h), 51.9 (g), 134.5 (c), 147.6 (a), 152.7 (e), 162.0 (f) IR (cm−1): 1593(s), 1381(m), 1359(m), 1277(m), 1206(m), 922(vs), 642(w), 557(vs), 438(s). MS: m/z 481.1420 (M+).
-
- Only the macrocyclic ligand for 1.1Y1a (i.e. that with a propyl bridge linking the two imine units) could be metallated by straightforward reaction of the macrocycle with a Au(III) salt using the method described for compound 1.1a. Complexes 1.1Y1b and 1.5Y1a had to be synthesized by a novel metal-templated reaction in which closure of the macrocycle through the formation of the bis(imine) links with the relevant diamine nucleophile occurs about the Au(III)-bound 2,3-bis(5′-formylpyrrol-2′-yl)quinoxaline moiety (i.e. metal-templated cyclization).
- Procedure for Compound 1.1Y1a
- The free ligand was synthesized following the literature method.41 A solution of tert-butylammonium tetrachloroaurate(III) (80 mg, 0.138 mmols) and tert-butylammonium hexafluorophosphate(V) (160 mg, 0.414 mmols) in dichloromethane (15 mL) was added dropwise to the free ligand, 12,13-dihydro-14H-6,9:17,20-diepimino[1,6]diazacyclo-heptadecino [12,13-b]quinoxaline (99 mg, 0.275 mmols) in dichloromethane (20 mL). The solution was refluxed for 16 hours. Over this time a precipitate formed which was filtered, washed with dichloromethane and dried to afford a brick red powder of {12,13-dihydro-14H-6,9:17,20-diepimino[1,6]diazacyclo-heptadecino[12,13-β]quinoxalinato}gold(III) hexafluorophosphate(V) (44 mg, 37%). Crystals suitable for single crystal X-ray diffraction were grown by vapor diffusion of diethylether into a benzonitrile solution of the product. 1H NMR (400 MHz, DMSO-d6): δ 2.42 (br, 2H, ═N—CH2—CH2), 3.94 (br, 4H, ═N—CH2—CH2), 7.25 (d, 3JHH=4.4 Hz, 2H, 3-pyrrole), 7.81 (d, 3JHH=4.4 Hz, 2H, 4-pyrrole), 7.94-7.96 (dd, 4JHH=3.3 Hz, 3JHH4.4 Hz, 3JHH=3.1 Hz, 2H, 6,7-quinoxaline), 8.05-8.07 (dd, 4JHH=3.3 Hz, 3JHH=3.1 Hz, 2H, 8,5-quinoxaline), 8.73 (s, 2H, —CH═N); 13C (100 MHz, DMSO-d6): δ 33.81, 51.27, 118.76, 122.46, 128.48, 131.69, 135.53, 138.99, 139.35, 147.54, 163.05; IR (cm−1): 2955 (br), 1649 (m), 1572 (w), 1472 (w), 1400 (m), 1294 (m),1115 (m), 1068 (w), 832 (s), 760 (s), 664 (w), 497 (s), 424 (m); UV-vis (CH3CN) λmax [nm] (ε/M−1 cm−1): 246 (23 346), 309 (30 077), 346 (18 001), 373 (15 237), 455 (12 041);); MS: m/z 549.1104 (M+).
- Procedure for Compound 1.1Y1b
- 2,3-Bis(5′-formylpyrrol-2′-yl)quinoxaline, alternatively named 5,5′-quinoxaline-2,3-diylbis(1H-pyrrole-2-carbaldehyde), was synthesized by the literature method41 A solution of 2,3-bis(5′-formylpyrrol-2′-yl)quinoxaline (54 mg, 0.172 mmols) in dichloromethane (10 mL) was added dropwise to tert-butylammonium tetrachloroaurate(III) (100 mg, 0.172 mmols) in dichloromethane (20 mL). The solution was allowed to reflux for 90 min before the
addition 1,3-diamino-2,2-dimethylpropane (18 mg, 0.172 mmols) whereupon a yellow solid immediately precipitates out of solution. The reaction mixture was refluxed for a further 30 min and after this time triethylamine (35 mg, 0.344 mmols) was added after which the precipitate turned orange. The reaction mixture was refluxed for 1 hour before the orange precipitate was isolated and dried. This precipitate was dissolved in methanol and a saturated solution of ammonium hexafluorophosphate(V) was added to precipitate out the hexafluorophosphate salt of the gold complex. The precipitate was filtered and dried to afford an orange powder of {12,14-dihydro-13,13-dimethyl-6,9:17,20-diepimino[1,6]diazacyclo-heptadecino[12,13-β]quinoxalinato}gold(III) hexafluorophosphate(V) (45 mg, 36%). 1H NMR (500 MHz, DMSO-d6): δ 1.19 (s, 6H, CH3), 3.72 (s, 4H, ═N—CH2—C(CH3)2), 7.44 (d, 3JHH=4.4 Hz, 2H, 3-pyrrole), 7.97-7.99 (dd, 4JHH=3.3 Hz, 3JHH=3.1 Hz, 2H, 6, 7-quinoxaline), 7.99 (d, 3JHH=4.4 Hz, 2H, 4-pyrrole), 8.17-8.19 (dd, 4JHH=3.3 Hz, 3JHH=3.1 Hz, 2H, 8,5-quinoxaline), 8.83 (s, 2H, —CH═N); 13C (125 MHz, DMSO-d6): δ 23.09, 43.05, 61.57, 119.35, 123.39, 129.08, 132.31, 136.73, 139.67, 140.03, 148.43, 164.56; IR (cm−1): 1569 (m), 1471 (w), 1405 (m),1339 (w), 1238 (w), 1107 (m), 835 (s), 557 (m), 433 (m); UV-vis (CH3CN) λmax [nm] (ε/M−1 cm−1): 230 (17 642), 249 (14 463), 309 (16 131), 348 (8 795), 375 (8 680), 458 (6 640), 481 (6 360); MS: m/z 577.1416 (M+). - Procedure for Compound 1.5Y1a
- This complex was prepared by the same method used for the synthesis of 1.1Y1b but with 1,4-diaminobutane (15.2 mg, 0.172 mmols) as the macrocycle-closing diamine to give a brown powder of compound 1.5Y1a, {12,13,14,15-tetrahydro-6,9:18,21-diepimino[1,6]diazacycloctadecino[12,13-b]quinoxalinato}gold(III) hexafluorophosphate(V) (20 mg, 16%). 1H NMR (500 MHz, DMSO-d6): δ 2.04 (br, 4H, ═N—CH2—CH2), 4.31 (br, 4H, ═N—CH2—CH2), 7.45 (d, 3JHH=4.4 Hz, 2H, 3-pyrrole), 7.95-7.97 (dd, 4JHH=3.3 Hz, 3JHH=3.1 Hz, 2H, 6,7-quinoxaoline), 8.06 (d, 3JHH=4.4 Hz, 2H, 4-pyrrole), 8.17-8.18 (dd, 4JHH=3.3 Hz, 3JHH=3.1 Hz, 2H, 8,5-quinoxaline), 8.74 (s, 2H, —CH═N); 13C (125 MHz, DMSO-d6): δ 23.68, 55.41, 118.92, 122.26, 128.52, 131.69, 135.69, 139.64, 139.72, 147.92, 164.83; IR (cm−1): 2964 (w), 1590 (m), 1400 (m), 1354 (m), 1100 (m), 1059 (m), 829 (s), 555 (s), 446 (w); UV-vis (CH3CN) λmax [nm] (ε/M−1 cm−1): 244 (16 439), 306 (19 364), 347 (13 712), 370 (13 425), 449 (9 825); MS: m/z 563.1265 (M+).
- Compound 1.1Y1e, {13-chloro-12,14-dihydro-6,9:17,20-diepimino[1,6]diazacyclo-heptadecino[12,13-β]quinoxalinato}gold(III) hexafluorophosphate(V), was similarly synthesized.
- Table 2 shows a summary of X-Ray data of some of the gold(III) chelates of the invention.
-
TABLE 2 Summary of X-Ray data of some of the gold(III) chelates of the invention Crystal Data Formula C13H14AuF6N4OP C15H19AuClN4O0.5 C12H12AuF6N4P Compound number MA_AuOH (1.1c) MA_AuDM (1.1b) MA_AuEn (1.2a) Cell Setting Monoclinic Monoclinic Orthorhombic Space Group P21/n P21/c Pbcn Formula Weight 584.22 495.76 554.2 a/Å 7.6496(2) 13.5985(3) 10.0520(5) b/Å 11.8256(4) 11.9234(3) 20.1960(5) c/Å 18.8218(6) 19.7476(5) 8.2450(5) α/°; β/°; γ/° 90; 101.181(3); 90 90; 97.299(2); 90 90; 90; 90 T/K 131(2) 140(2) 298(2) Z 4 4 4 V/Å3 1670.32(9) 3175.94(13) 1673.82(14) Density (g cm−3) 2.323 2.074 2.20 F(000) 1104 1896 1039.7 μ (mm−1) 8.977 9.435 8.948 Crystal Dim. (mm3) 0.05 × 0.10 × 0.40 0.45 × 0.45 × 0.45 0.07 × 0.1 × 0.40 Radiation M0 Kα (Å) 0.71073 Total data collected 17500 31771 16589 Unique Data 3297 6250 1665 Rint 0.0302 0.0741 0.068 Refinement Method Full-matrix least-squares on F2 Final R indices R1 = 0.0206 R1 = 0.0424 R1 = 0.050 [I > 2sigma(I)] wR2 = 0.0399 wR2 = 0.121 wR2 = 0.140 Final R indices R1 = 0.0286 R1 = 0.0479 R1 = 0.072 [all data] wR2 = 0.0413 wR2 = 0.1238 wR2 = 0.154 Crystal Data Formula C15H17AuF6N4OP C15H16AuClF6N5P C17H14AuF6N5O Compound number MA_AuOEt (1.1d) MA_AuCl (1.1e) MA_AuTol (1.3b) Cell Setting Monoclinic Monoclinic Monoclinic Space Group P21/n P21/n P21/n Formula Weight 611.3 643.7 533.3 a/Å 8.2220(5) 11.3580(3) 17.7717(12) b/Å 10.5390(5) 12.5390(5) 8.9015(7) c/Å 21.1170(5) 13.9730(4) 22.696(16) α/°; β/°; γ/° 90; 95.430(5); 90 90; 106.490(5); 90 90; 102.530(7); 90 T/K 100(2) 100(2) 298(2) Z 4 4 8 V/Å3 1821.61(17) 1908.16(32) 3504.89(56) Density (g cm−3) 2.229 2.24 2.02 F(000) 1164 1223.7 2031.3 μ (mm−1) 8.237 8.003 8.422 Crystal Dim. (mm3) 0.10 × 0.10 × 0.60 0.07 × 0.10 × 0.60 0.02 × 0.15 × 0.50 Radiation M0 Kα (Å) 0.71073 Total data collected 12681 18903 10005 Unique Data 3607 6137 5945 Rint 0.0542 0.041 0.061 Refinement Method Full-matrix least-squares on F2 Final R indices R1 = 0.0536 R1 = 0.040 R1 = 0.079 [I > 2sigma(I)] wR2 = 0.1516 wR2 = 0.101 wR2 = 0.179 Final R indices R1 = 0.0598 R1 = 0.051 R1 = 0.133 [all data] wR2 = 0.1546 wR2 = 0.105 wR2 = 0.194 -
- [1] P. Zatta, Coordination Chemistry Reviews, 2009, (253), 1597-1598.
- [2] I. Kostova, Anti Cancer Agents in Medicinal Chemistry, 2006, (6), 19-32.
- [3] M. Rigobello, G. Scutari, R. Boscolo and A. Bindoli, British Journal of Pharmacology, 2002, (136), 1162-1168.
- [4] S. Gunatilleke and A. Barrios, Journal of Medicinal Chemistry, 2006, (49), 3933-3937.
- [5] V. Milacic and P. Dou, Coordination Chemistry Reviews, 2009, (253), 1649-1660.
- [6] L. Ronconi, L. Giovagnini, C. Marzano, F. Betti'o, R. Graziani, G. Pilloni, and D. Fregona, Inorganic Chemistry, 2005, (44), 1867-1881.
- [7] L. Ronconi, C. Marzano, P. Zanello, M. Corsini, G. Miolo, C. Macca, A. Trevisan, and D. Fregona, Journal of Medicinal Chemistry, 2006, (49), 1648-1657.
- [8] L. Messori, F. Abbate, G. Marcon, P. Orioli, M. Fontani, E. Mini, T. Mazzei, S. Carotti, T. O'Connell, and P. Zanello, Journal of Medicinal Chemistry, 2000, (43), 3541-3548.
- [9] G. Marcon, S. Carotti, M. Coronnello, L. Messori, E. Mini, P. Orioli, T. Mazzei, M. A. Cinellu, and G. Minghetti, Journal of Medicinal Chemistry, 2002, (45), 1672-1677.
- [10] I. Ott, Coordination Chemistry Reviews, 2009, (253), 1970-1981.
- [11] P. Calamai, S. Carotti, A. Guerri, L. Messori, E. Mini, P. Oriolli and G. P. Speroni, Journal of Inorganic Biochemistry, 1997, (66), 103-109.
- [12] A. Garza-Ortiz, H. den Dulk, J. Brouwer, H. Kooijman, A. L. Spek, J. Reedijk, Journal of Inorganic Biochemistry, 2007, (101), 1922-1930.
- [13] R. W.-Y. Sun, C.-M. Che, Coordination Chemistry Reviews, 2009, (253), 1682-1691
- [14] O. Munro and G. Camp, Acta Crystallographica Section C, 2003, (C59), o672-o675.
- [15] C. Stern, F. Franceschi, E. Solari, C. Floriani and R. Scopelliti, Journal of Organometallic Chemistry, 2000, (593), 86-95.
- [16] A. Bacchi, M. Carcelli, L. Gabba, S. Ianelli, P. Pelagatti, G. Pelizzi, D. Rogolino, Inorganica Chimica Acta, 2003, (342), 229-235.
- [17] N. Bailey, S. Hull, Crystal Structure Communications, 1976, (5) 447-451.
- [18] U. Mueller-Westerhoff, A. Rheingold and M. Allen, 1996, Private communication to the Cambridge Structural Database. Reference No. 219663. Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge England.
- [19] F. Franceschi, G. Guillemot, E. Solari, C. Floriani, H. Birkedal and P. Patterson, Chemistry:A European Journal, 2001, (7), 1468-1478.
- [20] H. Yokoi and W. Addison, Inorganic Chemistry, 1977, (16), 1341-1349.
- [21] C. Berube, S. Gambarotta, G. Yap and P. Cozzi, Organometallics, 2003, (22), 434-439.
- [22] Hai-Feng Xiang, Siu-Chung Chan, Kitty Kit-Ying Wu, Chi-Ming Che and P. T. Lai, Chemical Communications, 2005, 1408-1410.
- [23] Jing-Wen Ran, Dao-Jun Onga, and Ya-Hong Li, Acta Crystallographica Section E, 2006, (E62), m2668-m2669.
- [24] Y. Wang, H. Fu, A. Peng, Y. Zhao, J. Ma, Y. Maa and J. Yao, Chemical Communications, 2007, 1623-1625.
- [25] B. B. Hasinoff, X. Wu, O. V. Krokhin, W. Ens, K. G. Standing, J. L. Nitiss, T. Sivaram, A. Giorgianni, S. Yang, Y. Jiang, and J. C. Yalowich, Molecular Pharmacology, 2005, (67), 937-947.
- [26] L. H. Jensen, H. Liang, R. Shoemaker, M. Grauslund, M. Sehested and B. B. Hasinoff, Molecular Pharmacology, 2006, (70), 1503-1513.
- [27] J. M. Fortune and N. Osheroff, Prog. Nucleic Acid Res. Mol. Biol., 2000, (64), 221-253.
- [28] B. B. Hasinoff, Cardiovasc. Toxicol., 2002, (2), 111-118.
- [29] L. H. Jensen, M. Sehested, U.S. Patent: US20090209535A1.
- [30] J. G. Hengstler, C. K. Heimerdinger, I. B. Schiffer, S. Gebhard, J. Sagemmüller, B. Tanner, H. M. Bolt, F. Oesch, EXCLI Journal, 2002, (1), 8-14.
- [31] A. Bacchi, M. Carcelli, L. Gabba, S. lanelli, P. Pelagatti, G. Pelizzi, D. Rogolino, Inorg. Chim. Acta, 2003, (342), 229.
- [32] L.-M. Chen, J. Liu, J.-C. Chen, C. P. Tan, S. Shi, K.-C. Zheng, L.-N. Ji, J. Inorg. Biochem., 2008, (102), 330-341.
- [33] A. Andersson, H. Ehrsson, J. Pharm. Biomed. Anal., 1995, (13), 639-644.
- [34] J. Lagona, P. Mukhopadhyay, S. Chakrabarti, L. Isaacs, Angew. Chem. Int. Ed. 2005, (44), 4844-4870.
- [35] T. G. Appleton and J. R. Hall, Inorganic Chemistry, 1972, (11), 112-117.
- [36] P. Nanjappan, N. Raju, K. Ramalingam, D. P. Nowotnik, Tetrahedron, 1994, (50), 8617-8632.
- [37] P. Di Bernardo, P. L. Zanonato, S. Tamburini and P. A. Vigato, Inorganica Chimica Acta, 2007, (360), 1083-1094.
- [38] K. Ramalingam, N. Raju, P. Nanjappan, N. Palaniappa and P. David, Tetrahedron, 1995, (51), 2875-2894.
- [39] F. Taehee Kang, E. Yoon, E. Choi, S. Kim, J. Lee, European Journal of Medicinal Chemistry, 2009, (44), 239-250.
- [40] S. L. Barnholtz, J. D. Lydon, G. Huang, M. Venkatesh, C. L. Barnes, A. R.
- Ketring, and S. S. Jurisson, Inorganic Chemistry, 2001, (40), 972-976.
- [41] L. Wang, X.-J. Zhu, W.-Y. Wong, J.-P. Guo, W.-K. Wong, Z.-Y. Li, Dalton. Trans., 2005, 3235-3240.
Claims (25)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA201004299 | 2010-06-17 | ||
ZA2010/04299 | 2010-06-17 | ||
PCT/IB2011/052572 WO2011158176A2 (en) | 2010-06-17 | 2011-06-14 | Gold complexes |
Publications (2)
Publication Number | Publication Date |
---|---|
US20130090472A1 true US20130090472A1 (en) | 2013-04-11 |
US9346832B2 US9346832B2 (en) | 2016-05-24 |
Family
ID=44532964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/704,894 Active 2032-01-08 US9346832B2 (en) | 2010-06-17 | 2011-06-14 | Gold complexes for use in the treatment of cancer |
Country Status (3)
Country | Link |
---|---|
US (1) | US9346832B2 (en) |
WO (1) | WO2011158176A2 (en) |
ZA (1) | ZA201209452B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019005876A1 (en) * | 2017-06-26 | 2019-01-03 | Rohde Kyle H | Activity gold-complexed compounds against mycobacterium tuberculosis and mycobacterium abcessus |
WO2022171883A2 (en) | 2021-02-15 | 2022-08-18 | Szczepaniak Stanislaw | Water-soluble complexes of gold (iii) in medical uses |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL236093B1 (en) | 2017-07-04 | 2020-11-30 | Dominika Szczepaniak | Water-soluble intelligent gold complexes (III), method for producing water-soluble intelligent gold complexes (III) and their application |
CN112358430B (en) * | 2020-11-02 | 2022-09-09 | 南方科技大学 | Schiff base metal complex and preparation method thereof, perovskite solar cell and preparation method thereof |
US20240174703A1 (en) * | 2021-03-04 | 2024-05-30 | University Of Kentucky Research Foundation | Three-coordinate au(i) probes and use in selectively disrupting mitochondria in cancer cells |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688487A (en) * | 1991-10-29 | 1997-11-18 | Bracco International B.V. | Diagnostic imaging methods using rhenium and technetium complexes containing a hypoxia-localizing moiety |
US20130259903A1 (en) * | 2009-07-08 | 2013-10-03 | Mark Gordon Mortenson | Novel Gold-Based Nanocrystals for Medical Treatments and Electrochemical Manufacturing Processes Therefor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040063681A1 (en) | 2002-09-16 | 2004-04-01 | Chi-Ming Che | Methods for using gold (III) complexes as anti-tumor and anti-HIV agents |
-
2011
- 2011-06-14 US US13/704,894 patent/US9346832B2/en active Active
- 2011-06-14 WO PCT/IB2011/052572 patent/WO2011158176A2/en active Application Filing
-
2012
- 2012-12-12 ZA ZA2012/09452A patent/ZA201209452B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688487A (en) * | 1991-10-29 | 1997-11-18 | Bracco International B.V. | Diagnostic imaging methods using rhenium and technetium complexes containing a hypoxia-localizing moiety |
US20130259903A1 (en) * | 2009-07-08 | 2013-10-03 | Mark Gordon Mortenson | Novel Gold-Based Nanocrystals for Medical Treatments and Electrochemical Manufacturing Processes Therefor |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019005876A1 (en) * | 2017-06-26 | 2019-01-03 | Rohde Kyle H | Activity gold-complexed compounds against mycobacterium tuberculosis and mycobacterium abcessus |
WO2022171883A2 (en) | 2021-02-15 | 2022-08-18 | Szczepaniak Stanislaw | Water-soluble complexes of gold (iii) in medical uses |
Also Published As
Publication number | Publication date |
---|---|
ZA201209452B (en) | 2013-08-28 |
WO2011158176A2 (en) | 2011-12-22 |
WO2011158176A3 (en) | 2012-04-19 |
US9346832B2 (en) | 2016-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yilmaz et al. | Synthesis, structures and anticancer potentials of platinum (II) saccharinate complexes of tertiary phosphines with phenyl and cyclohexyl groups targeting mitochondria and DNA | |
Revathi et al. | Biologically active Cu (II), Co (II), Ni (II) and Zn (II) complexes of pyrimidine derivative Schiff base: DNA binding, antioxidant, antibacterial and in vitro anticancer studies | |
Kakoulidou et al. | Zn (II) complexes of (E)-4-(2-(pyridin-2-ylmethylene) hydrazinyl) quinazoline in combination with non-steroidal anti-inflammatory drug sodium diclofenac: Structure, DNA binding and photo-cleavage studies, antioxidant activity and interaction with albumin | |
Devi et al. | Synthesis, interaction with DNA, cytotoxicity, cell cycle arrest and apoptotic inducing properties of ruthenium (II) molecular “light switch” complexes | |
US9346832B2 (en) | Gold complexes for use in the treatment of cancer | |
Colina-Vegas et al. | Ru (II)/clotrimazole/diphenylphosphine/bipyridine complexes: Interaction with DNA, BSA and biological potential against tumor cell lines and Mycobacterium tuberculosis | |
Kiran et al. | Synthesis, spectroscopic characterization and in vitro studies of new heteroleptic copper (II) complexes derived from 2-hydroxy napthaldehyde Schiff’s bases and N, N donor ligands: Antimicrobial, DNA binding and cytotoxic investigations | |
Lazou et al. | Transition metal complexes with a novel guanine-based (E)-2-(2-(pyridin-2-ylmethylene) hydrazinyl) quinazolin-4 (3H)-one: Synthesis, characterization, interaction with DNA and albumins and antioxidant activity | |
Zhang et al. | Two dpa-based zinc (ii) complexes as potential anticancer agents: nuclease activity, cytotoxicity and apoptosis studies | |
Khan et al. | Gold (I), silver (I) and copper (I) complexes of 2, 4, 6-trimethylphenyl-3-benzoylthiourea; synthesis and biological applications | |
Mazur et al. | Synthesis, crystal structure and biological activities of a novel amidrazone derivative and its copper (II) complex—A potential antitumor drug | |
Kalaiarasi et al. | An investigation on 3-acetyl-7-methoxy-coumarin Schiff bases and their Ru (II) metallates with potent antiproliferative activity and enhanced LDH and NO release | |
Martin-Santos et al. | Gold (III) complexes with hydroxyquinoline, aminoquinoline and quinoline ligands: Synthesis, cytotoxicity, DNA and protein binding studies | |
Abosede et al. | Copper (II) mixed-ligand polypyridyl complexes with doxycycline–structures and biological evaluation | |
Gao et al. | Four related mixed-ligand nickel (II) complexes: effect of steric encumbrance on the structure, DNA/BSA binding, DNA cleavage and cytotoxicity | |
Purkait et al. | Alteration of steric hindrance modulates glutathione resistance and cytotoxicity of three structurally related Ru II-p-cymene complexes | |
Massoud et al. | Copper (II) complexes based on tripodal pyridyl amine derivatives as efficient anticancer agents | |
Nolan et al. | Indole-containing arene-ruthenium complexes with broad spectrum activity against antibiotic-resistant bacteria | |
Green et al. | The influence of the ancillary ligand on the potential of cobalt (III) complexes to act as chaperones for hydroxamic acid-based drugs | |
Rigamonti et al. | From solid state to in vitro anticancer activity of copper (II) compounds with electronically-modulated NNO Schiff base ligands | |
Moharana et al. | Drive to organoruthenium and organoiridium complexes from organoplatinum: Next-generation anticancer metallotherapeutics | |
Li et al. | Synthesis, crystal structures and antitumor activity of two platinum (II) complexes with methyl hydrazinecarbodithioate derivatives of indolin-2-one | |
Hegde et al. | Transition metal complexes of N′-(2-(hydroxyimino) propanoyl) isonicotinohydrazide: Synthesis, characterization, DNA interaction and anticancer evaluation | |
Hammud et al. | Structure, DFT studies, magnetism and biological activity of bis [(µ-azido)-chloro-(1, 10-phenanthroline)-copper (II)] complex | |
Kalaiarasi et al. | Biological evaluation of new organoruthenium (II) metallates containing 3-acetyl-8-methoxy-2H-chromen-2-one appended CNS donor Schiff bases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF KWAZULU-NATAL, SOUTH AFRICA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUNRO, ORDE QUENTIN;AKERMAN, KATE JULIE;AKERMAN, MATTHEW PIERS;SIGNING DATES FROM 20120116 TO 20120201;REEL/FRAME:029612/0620 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: 7.5 YR SURCHARGE - LATE PMT W/IN 6 MO, LARGE ENTITY (ORIGINAL EVENT CODE: M1555); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |